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ABSTRACT 
Bladder pain syndrome (BPS)/interstitial cystitis (IC) is a chronic pain disorder 
characterized by at least six weeks of lower urinary tract symptoms and unpleasant 
sensations (pain, pressure and discomfort) thought to be related to the urinary bladder and 
not meeting exclusion criteria. While the etiology is not known, BPS/IC may involve a 
“vicious circle” of uroepithelial dysfunction, inflammation and peripheral and central 
sensitization. We propose that the urinary bladder inflammatory insult partly mediates 
voiding dysfunction and visceral neurogenic pain characteristic of BPS/IC. Several 
studies from our laboratory have already demonstrated the role(s) of cytokines and their 
downstream targets in the functional alterations in micturition reflex pathways following 
chemically (cyclophosphamide, CYP)-induced cystitis. More recently, the pleiotropic 
protein, TGF-β, has been implicated in the pathogenesis of CYP-induced cystitis. 
TGF-β is activated locally at the initial site of injury by protease-dependent or 
protease-independent mechanisms to initiate a proinflammatory milieu. Depending on its 
contextual cues, TGF-β may then aid in resolving the primary immune response and 
support tissue repair. Though TGF-β is necessary to maintain normal immunological 
function, its aberrant expression and activation may have detrimental effects on 
responding tissues and cell types. A sustained increase in peripheral TGF-β reactivity, 
such as what may be observed in chronic inflammatory bladder conditions, may influence 
bladder afferent excitability to amplify nociceptive transmission and CNS input. The 
subsequent sensitization of peripheral afferent nociceptors at the level of the DRG or 
urothelium may promote spinal cord ‘wind-up’ and cascade into visceral hyperalgesia 
and allodynia. 
In the first aim of this dissertation we investigated the functional profile of TGF-β 
isoforms and receptor (TβR) variants in the normal and inflamed (CYP-induced cystitis) 
urinary bladder with qRT-PCR, ELISA, IHC and in vivo cystometry. Our studies 
determined (i) the involvement of TGF-β in lower urinary tract neuroplasticity following 
urinary bladder inflammation, (ii) a functional role for TGF-β signaling in the afferent 
limb of the micturition reflex and (iii) urinary bladder TβR-1 as a viable target to reduce 
voiding frequency with cystitis. In the second aim of this dissertation we investigated the 
sensory components of the urinary bladder that may underlie the pathophysiology of 
aberrant TGF-β activation with bladder-pelvic nerve electrophysiology and luciferin-
luciferase assays for ATP measurement. Our studies determined that TGF-β1 increased 
bladder afferent nerve excitability by stimulating ATP release from the urothelium via 
vesicular exocytosis mechanisms with minimal contribution from pannexin-1 channels. 
Furthermore, blocking aberrant TGF-β signaling in CYP-induced cystitis with TβR-1 
inhibition decreased afferent nerve excitability with an equivalent decrease in ATP 
release. 
Taken together, these results establish a causal link between an inflammatory 
mediator, TGF-β, and intrinsic signaling mechanisms of the urothelium that may 
contribute to the altered sensory processing of bladder filling to facilitate increased 
voiding frequency. The distinct interactions of multiple mediators underscore the 
challenges for single target therapies and support the development of combinatory 
therapeutics for bladder dysfunction. Ultimately, these studies have increased our 
understanding of functional disorders and visceral pain and have the potential to improve 
the health of those suffering from inflammation-associated bladder syndromes.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW 
1.1. Lower Urinary Tract 
1.1.1. Anatomy 
The lower urinary tract (LUT, bladder and urethra) is a division of the renal 
system that functions to passively store kidney byproducts until it is appropriate to void. 
To accomplish this, the urinary bladder is a muscular and membranous organ whose 
structure embodies its reservoir function. Its external features are organized into an apex, 
fundus, body and neck. The apex, or vertex, is on the anterior surface of the urinary 
bladder and is associated with ligament remnants attaching to the umbilicus (Tank, 2009). 
The posterior surface is the fundus and its most inferior aspect is termed the base of the 
urinary bladder (Tank, 2009). The body typically represents the area between the apex 
and the fundus and the bladder neck is the most caudal aspect of the inferior bladder 
surface that is perforated by the internal urethral orifice (Tank, 2009).  
The urinary bladder wall is divided into three layers: tunica mucosa, tunica 
muscularis propria and tunica serosa/adventitia (Figure 1). The tunica mucosa consists of 
transitional epithelium and a lamina propria (Figure 1). Transitional epithelial cells in the 
urinary bladder are termed the urothelium and are arranged in basal, intermediate and 
apical cell layers. Basal cells are monolayers directly attached to the basement membrane 
(Lewis, 2000). Intermediate cells are generally larger in diameter than basal cells and 
range from one to multiple cell layers depending on the species (Lewis, 2000). The 
apical, or umbrella, cells are hexagonal in shape and range from 25-250 μm depending on 
urinary bladder distention (L. A. Birder & K. E. Andersson, 2013; Lewis, 2000). 
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Several distinct features of the luminal surface of umbrella cells establish 
antiadherence and an impermeable barrier characteristic of the urinary bladder mucosa. 
First, tight junction complexes comprised of occludin and claudin proteins regulate 
paracellular transport between adjacent umbrella cells (L. A. Birder & K. E. Andersson, 
2013). The apical membrane is also occupied by uroplakin, a crystalline plaque cell 
surface protein that forms an asymmetric unit membrane to maintain impermeability 
during bladder expansion (X. R. Wu, Kong, Pellicer, Kreibich, & Sun, 2009). Lastly, a 
layer of proteoglycans on the mucosal surface of umbrella cells serves as an 
antiadherence factor and provides yet another physical barrier between urinary 
constituents and the lamina propria (Figure 1) (Janssen et al., 2013).  
The extracellular matrix of the lamina propria is deep to the basement membrane 
of the urothelium and contains a diverse array of interstitial cells, nerve terminals and 
vasculature (Figure 1) (Andersson & McCloskey, 2013; L. A. Birder & K. E. Andersson, 
2013). It has been suggested that the lamina propria may have an important role in 
integrating epithelial and smooth muscle function due to its innervations and proximity to 
the urothelium and tunica muscularis propria (Andersson & McCloskey, 2013). The 
tunica muscularis propria consists of three smooth muscle layers termed the detrusor 
(Figure 1). The internal and external layers are arranged longitudinally, whereas those in 
the middle are circular (Andersson & Arner, 2004; Krstic, 2004). The smooth muscle 
cells in the muscularis propria retain their classic spindle shape and are bundled together 
by collagen-rich connective tissue (Andersson & Arner, 2004). External to the muscularis 
propria, the tunica serosa surrounds the superior and lateral surfaces of the urinary 
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bladder wall, whereas, the retroperitoneal aspects contain a vascular, loose connective 
tissue termed the tunica adventitia (Figure 1) (Krstic, 2004).  
Caudal to the inferior surface of the urinary bladder is the urethra. Similar to the 
urinary bladder wall, the urethral wall is composed of a tunica mucosa, tunica muscularis 
propria and tunica adventitia. The tunica mucosa consists of transitional epithelium 
proximal to the urinary bladder followed by nonkeratinized, stratified squamous 
epithelium distally (Krstic, 2004; Yucel & Baskin, 2004). The tunica muscularis propria 
is composed of inner and outer smooth muscle arranged longitudinally and circularly, 
respectively (Krstic, 2004). In the male urethra, the circular smooth muscle fascicles join 
with urinary bladder smooth muscle at the urethrovesical junction to form the internal 
urethral sphincter (Krstic, 2004; Yucel & Baskin, 2004). The smooth muscle fascicles 
along the proximal female urethra, however, do not appear to anatomically arrange into a 
sphincter (Yucel & Baskin, 2004). Skeletal muscle of the urethral wall forms the external 
urethral sphincter and extends along the membranous urethra in males to generate 
voluntary pressure during bladder filling (Fowler, Griffiths, & de Groat, 2008). The 
skeletal muscle fibers in the female urethra join to form an ‘external’ urethral sphincter 
comprised of a sphincter urethrae, compressor urethrae and sphincter urethrovaginalis to 
provide urinary continence through urethral and vaginal closure (Ashton-Miller & 
DeLancey, 2007). 
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Figure 1: Urinary bladder wall anatomy 
Left: Stained human urinary bladder. Right: Tissues and cell types within the bladder wall. The mucosa 
layer is comprised of the urothelium and the lamina propria that contains vasculature, lymphatics, nerves 
and smooth muscle cells. The muscularis propria is comprised of detrusor smooth muscle cells and 
surrounded by outer connective tissue layer termed the adventitia or serosa. Reprinted from BJU 
International, 96(4), Neuhaus, J., Pfeiffer, F., Wolburg, H., Horn, L., Dorschner, W., Alterations in 
connexin expression in the bladder of patients with urge symptoms, 670-676, Copyright (2005), with 
permission from John Wiley and Sons. Reprinted from Physiological Review, 93(2), Birder, L., Andersson, 
K.E., Urothelial signaling, 653-680, Copyright (2013), with permission from The American Physiological 
Society. 
 
1.1.2. Neural Control 
 The LUT is regulated by supraspinal, spinal and peripheral nervous system 
(PNS) input to maintain “switch-like” patterns of storage and elimination activity and has 
been previously reviewed in greater detail (Figure 2) (Fowler et al., 2008). Briefly, 
bladder wall mechanoreceptors initiate visceral afferent (Aδ fibers) activity during the 
storage phase that synapse on spinal interneurons (de Groat & Wickens, 2013; Fowler et 
al., 2008). Spinal reflex pathways then facilitate storage by directly enhancing 
thoracolumbar sympathetic outflow and somatomotor discharge or ascending, in some 
species, to metencephalic integration centers (Figure 2) (de Groat & Wickens, 2013; 
Fowler et al., 2008). 
5 
   
 Spinal interneurons activate preganglionic sympathetic fibers from the 
intermediolateral cell column of the lower thoracic (T10) through upper lumbar (L2) 
spinal cord that form thoracic and lumbar splanchnic nerves (Beckel & Holstege, 2011; 
Ochodnicky, Uvelius, Andersson, & Michel, 2013). The preganglionic fibers then 
synapse on the prevertebral inferior mesenteric ganglia or paravertebral ganglia and 
travel along the hypogastric and pelvic nerves, respectively (Fowler et al., 2008). 
Sympathetic adrenergic neurotransmission on the urinary bladder smooth muscle β-
adrenergic receptors promotes bladder wall relaxation and accommodation (Ochodnicky 
et al., 2013). Bladder filling is also facilitated by the activation of α-adrenergic receptors 
on the internal urethral sphincter resulting in contraction of the urethral outlet 
(Ochodnicky et al., 2013). Spinal reflex pathways not only enhance sympathetic outflow 
but also α-motoneuron discharge from Onuf’s nucleus in the ventrolateral horn of the 
sacral (S2-S4) spinal cord (Figure 2) (de Groat & Wickens, 2013). Propagation of this 
signal along the pudendal nerve to the external urethral sphincter elicits skeletal muscle 
contraction by activating nicotinic acetylcholine receptors to provide voluntary control 
over urinary continence (Ochodnicky et al., 2013). 
 Upon reaching the tension threshold, bladder afferents (Aδ fibers) bypass local 
spinal reflexes and ascend to the mesencephalic periaqueductal gray (PAG) (Figure 2). 
Unlike the reflexes underlying the storage phase, the elimination phase relies on 
supraspinal circuitry as evidenced by voiding dysfunction following lower thoracic spinal 
cord injury (Beckel & Holstege, 2011; de Groat & Yoshimura, 2006). After cortical 
processing, the PAG sends excitatory input to a region in the dorsolateral pontine 
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tegmentum termed the pontine micturition center (PMC) (Griffiths, 2002). The PMC then 
sends descending cortical projections that synapse on preganglionic parasympathetic 
neurons and inhibitory interneurons in the sacral spinal cord (Figure 2) (Beckel & 
Holstege, 2011; Griffiths, 2002).  
 The preganglionic parasympathetic fibers arise from the intermediolateral cell 
column of the human sacral (S2-S4) spinal cord to form pelvic nerves. Upon coursing 
through and exiting the hypogastric and pelvic plexus, the fibers join the pelvic and 
pudendal nerves to synapse on terminal ganglia and innervate the detrusor smooth muscle 
and urethra (de Groat & Wickens, 2013; Ochodnicky et al., 2013). Cholinergic and non-
adrenergic/non-cholinergic neurotransmission on the urinary bladder smooth muscle 
promotes bladder wall contraction by activating muscarinic acetylcholine receptors and 
purinergic receptors, respectively (Beckel & Holstege, 2011). Elimination of urine is also 
facilitated by nitric oxide release onto the internal urethral sphincter resulting in a 
relaxation of the urethral outlet (Beckel & Holstege, 2011). The PMC not only augments 
parasympathetic outflow but also attenuates preganglionic sympathetic and α-
motoneuron discharge to the LUT (Figure 2) (Griffiths, 2002). The descending cortical 
projections terminating on inhibitory interneurons in the sacral spinal cord prevents 
excitatory input into the urethral sphincters resulting in dilation of the urethral orifice and 
continuous flow of urine. As distention of the urinary bladder decreases during the 
elimination phase, ascending excitation to the dorsolateral metencephalon is diminished 
and the storage phase is once again switched on. 
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Figure 2: Neural control of continence and micturition 
a: Storage reflex. Bladder wall mechanoreceptors initiate visceral afferent activity during the storage phase. 
Spinal reflex pathways then facilitate storage by enhancing sympathetic discharge in the hypogastric nerve 
and somatomotor discharge in the pudendal nerve. In some species, the pontine storage center may also 
promote urethral contraction. Together, this has a net effect of contracting the urethra and relaxing the 
detrusor smooth muscle to accommodate bladder filling. b: Micturition reflex. Upon reaching the tension 
threshold, afferent nerve discharge in the pelvic nerve ascends to the pontine micturition center and/or the 
periaqueductal gray (PAG). Descending cortical projections then activate parasympathetic discharge and 
inhibit sympathetic and somatomotor discharge. This has a net effect of promoting bladder wall 
contraction, relaxing the urethra and facilitating the elimination of urine. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Neuroscience, Fowler C.J., Griffiths D., de Groat W.C.. The 
neural control of micturition. 9(6):453-466, copyright (2008). 
 
1.1.3. Symptoms and Dysfunction 
The terminology used in the following section is consistent with the 
standardization report of LUT symptoms and function by the International Continence 
Society and will refer to their definitions when appropriate (Abrams et al., 2002). Similar 
to other clinical indications, LUT symptoms are the patient’s qualitative representation of 
a purported condition. These symptoms, in particular, refer to a spectrum of LUT 
functions that include storage, elimination and post micturition disturbances.  
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Symptoms associated with the storage phase include, but are not limited to, 
“increased frequency, urgency and incontinence” (Abrams et al., 2002).  The complaint 
of increased urinary frequency is prevalent among both men and women with LUT 
dysfunction and has been suggested to affect an individual’s quality of life as 
demonstrated by a strong correlation between frequency and bothersome endorsements 
(Coyne et al., 2009). Increased urgency is a complaint of the “sudden compelling desire 
to pass urine” that may be accompanied by pain, pressure or discomfort associated with 
the LUT (Abrams et al., 2002). Lastly, urinary incontinence includes a complaint of the 
“involuntary leakage of urine” and may manifest in various forms and severities (Abrams 
et al., 2002). It is important to note that incontinence is not representative of one 
particular LUT dysfunction but rather can arise from multiple sources including stress, 
comorbid disorders and congenital abnormalities (Cameron, Heidelbaugh, & Jimbo, 
2013). 
Symptoms associated with the elimination phase include “hesitancy, slow or 
intermittent stream, straining and terminal dribble” (Abrams et al., 2002). These 
symptoms generally involve complaints of the initiation and continuation of voiding and 
alterations to their urine stream and appear to be more prevalent in men compared to 
women (Abrams et al., 2002; Coyne et al., 2009). Symptoms associated with the post 
micturition phase occur after voiding and include “incomplete emptying and post 
micturition dribble” (Abrams et al., 2002). Although equally bothersome, post micturition 
dribble may be more prevalent in men, whereas in women, incomplete emptying may be 
more prevalent (Coyne et al., 2009). As briefly mentioned above, LUT symptoms are not 
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confined to urodynamic disturbances, but may also include unpleasant sensations of pain 
or discomfort during storage or elimination. These sensations are generally perceived to 
emanate from the urogenital organs and may exacerbate storage and elimination 
symptoms (Le & Schaeffer, 2009). 
1.2. Bladder Pain Syndrome/Interstitial Cystitis 
1.2.1. Background 
LUT signs and symptoms resembling what is currently termed bladder pain 
syndrome (BPS)/interstitial cystitis (IC) have been documented throughout history and its 
perspective has been previously reviewed in detail (Hanno, 2011). Briefly, Drs. Philip 
Syng Physick and Joseph Parish first recognized an inflammatory condition called tic 
doloureux of the bladder whose symptoms included chronic urinary frequency, urgency 
and pelvic pain (J. K. Parsons & Parsons, 2004). Skene (Skene, 1887) expanded the 
cystoscopic features of this concept in the late 19th century and introduced the term IC 
which included ulceration of the mucous membrane and inflammation within the bladder 
wall. Focal, ulcerative bleeding in the urinary bladder wall remained a hallmark of IC 
due, in part, to the work of Hunner (Hunner, 1915) in the early 20th century (Hanno, 
2011). Many patients, however, were misdiagnosed as current estimates suggest only 5-
7% of those with BPS/IC present with bladder ulcerations (Hanno, 2011; Jones & 
Nyberg, 1997). 
 In the absence of a formal classification for IC, the National Institute of Diabetes 
and Digestive and Kidney Diseases (NIDDK) attempted to standardize its research 
definition in 1987 by establishing a diagnostic criteria (Hanno, Staskin, Krane, & Wein, 
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1990). The criteria included the presence of “glomerulations on cystoscopic examination 
or a classic Hunner ulcer, pain associated with the bladder, urinary urgency” and eighteen 
exclusion conditions (Hanno, 2011; Hanno et al., 1990). After several iterations and 
international consultations, the term IC was expanded to include BPS (Hanno et al., 2011; 
van de Merwe et al., 2008). The patient selection for BPS is based on “chronic pelvic 
pain, pressure or discomfort perceived to be related to the urinary bladder accompanied 
by at least one other urinary symptom such as persistent urge to void or frequency”, 
whereas, IC is “reserved for cystoscopic and histological features” (Abrams et al., 2002; 
van de Merwe et al., 2008). At this time, the terms BPS and BPS/IC are analogous and is 
defined by the American Urological Association Interstitial Cystitis Guidelines Panel as 
at least six weeks of LUT symptoms and unpleasant sensations perceived to be related to 
the urinary bladder and with no other clinically identifiable sources (Hanno et al., 2011).  
1.2.2. Epidemiology 
 The epidemiology of BPS/IC is limited due to the absence of standardized 
definitions, markers and examinations (Berry et al., 2011; Hanno, 2011; Jones & Nyberg, 
1997; Sant & Hanno, 2001). Taking into account this variability, it is estimated that there 
is a 5:1 female-to-male ratio among BPS/IC patients (Hanno, 2011; Jones & Nyberg, 
1997). It is estimated that 300 per 100,000 women worldwide suffer from BPS/IC 
(Hanno, 2011). In the United States alone, 3.3 to 7.9 million women are estimated to 
meet the criteria for BPS/IC (Berry et al., 2011). As expected, BPS/IC puts an enormous 
financial burden on the individual and economy as a whole. Health care costs for an 
individual with BPS/IC ranges from 4 to 7 thousand dollars per year, while the economic 
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burden approaches 500 million dollars per year in lost productivity and therapeutics 
(Anger et al., 2011; Hanno, 2011).  
1.2.3. Pathophysiology 
 While the primary insult underlying BPS/IC is not known, it has been suggested 
that the pathophysiology is a “vicious circle” involving uroepithelial dysfunction, 
inflammation, afferent nerve hyperexcitability and visceral hyperalgesia and allodynia 
(Figure 3) (Sant, Kempuraj, Marchand, & Theoharides, 2007). This section will explore 
said mechanisms that have been proposed to feed-forward to promote the chronicity of 
LUT symptoms observed in BPS/IC (Sant et al., 2007). 
The urothelium is a specialized, stratified epithelium that when intact provides a 
non-adherent, passive barrier through tight junction proteins, plaque proteins and surface 
proteoglycans (Lewis, 2000). Any perturbation to the components of this permeability 
barrier may lead to increased infiltration into the bladder wall and exposure of the 
interstitium to urinary constituents (Hurst et al., 1996; C. L. Parsons, 2011; C. L. Parsons, 
Greene, Chung, Stanford, & Singh, 2005; C. L. Parsons & Hurst, 1990). The diffusion of 
urinary constituents like potassium into the bladder interstitium may depolarize muscle 
and nerve cells, inflame tissues, degranulate mast cells and cascade to the development of 
LUT symptoms (Figure 3) (C. L. Parsons, 2011). Uroepithelial dysfunction specific to 
BPS/IC, however, remains controversial. For example, Chelsky et al. (Chelsky et al., 
1994) demonstrated that the permeability in IC was comparable to the variation seen in 
symptom-free controls, whereas, Parsons et al. (C. L. Parsons et al., 2005) demonstrated 
abnormal permeability and potassium absorption in those with IC (Hanno, 2011). The 
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abundance of studies for or against uroepithelial dysfunction in BPS/IC suggest it may 
not be a primary insult but rather may occur in a subset of patients to exacerbate LUT 
symptoms (Hanno, 2011). 
In addition to the uroepithelial disruption, visceral inflammation also remains a 
central pathological process in BPS/IC and has been suggested to underlie the 
development of LUT symptoms (Figure 3). Inflammation within the urinary bladder 
viscera is characterized by increased vasculature, mucosal irritation that may result in 
barrier dysfunction and infiltration of inflammatory mediators (Erickson, Belchis, & 
Dabbs, 1997; Grover, Srivastava, Lee, Tewari, & Te, 2011). The proliferation and 
activation of mast cells, in particular, has received considerable attention in the urinary 
bladder immune response (Sant et al., 2007). Mast cells secrete vasoactive chemicals to 
promote innate and auto-immunity and their increased activity has been widely 
demonstrated in BPS/IC (W. Boucher, el-Mansoury, Pang, Sant, & Theoharides, 1995; 
Enerback, Fall, & Aldenborg, 1989; Kastrup, Hald, Larsen, & Nielsen, 1983; 
Theoharides et al., 1995). The subsequent exposure in the bladder interstitium to 
vasoactive chemicals, inflammatory mediators and neuropeptides from visceral 
inflammation may lead to afferent nerve hyperexcitability and neurogenic inflammation 
(Figure 3) (Vizzard, 2001; Yoshimura & de Groat, 1999; Y. Yu & de Groat, 2008). 
The loss of inhibition on peripheral afferents (Aδ and C fibers) increases input 
into the spinal cord and may eventually promote central sensitization (Sant et al., 2007). 
An unregulated state of central and peripheral reactivity causes ‘wind-up’ which is 
observed clinically as hyperalgesia and allodynia (Figure 3). In BPS/IC, hyperalgesia and 
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allodynia are characterized by an elevated state of urinary bladder sensation that may 
cause pain, pressure or discomfort and may result in increased urinary frequency and 
urgency (Grover et al., 2011).  The “vicious circle” continues as mast cell degranulation 
and infiltration of mediators from uroepithelial dysfunction and/or visceral inflammation 
sustain peripheral and central sensitization to establish visceral hyperalgesia/allodynia 
and chronic LUT symptoms (Figure 3) (Sant et al., 2007). 
 
Figure 3: Potential etiologic cascade and pathogenesis underlying BPS/IC 
It is likely that BPS/IC has a multifactorial etiology that may act predominantly through one or more 
pathways resulting in the typical symptom-complex. There is a lack of consensus regarding the etiology or 
pathogenesis of BPS/IC but a number of proposals include a “leaky epithelium,” release of neuroactive 
compounds at the level of the urinary bladder with mast cell activation, “awakening” of C-fiber bladder 
afferents, and upregulation of inflammatory mediators including cytokines and chemotactic cytokines 
(chemokines). Inflammatory mediators can affect CNS and PNS neural circuitry including central “wind-
up” and nociceptor sensitization resulting in chronic bladder pain and voiding dysfunction. BPS/IC is 
associated with diseases affecting other viscera and pelvic floors. Reprinted from Urology, 69(4 Suppl), 
Sant, G.R., Kempuraj, D., Marchand, J.E., Theoharides, T.C., The mast cell in interstitial cystitis: Role in 
pathophysiology and pathogenesis, S34-40, Copyright (2007), with permission from Elsevier. Reprinted 
from BioMed Research International, 2014, Gonzalez, E.J., Arms, L., Vizzard, M.A., The role(s) of 
cytokines/chemokines in urinary bladder inflammation and dysfunction, 1-17, Copyright (2014), with 
permission from Hindawi Publishing Corporation. 
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1.2.4. Animal Models 
 Numerous animal models have been implemented to determine the onset and 
chronicity of LUT dysfunctions like BPS/IC. While one model cannot currently account 
for the constellation of symptoms in BPS/IC, they each aid in identifying distinct 
mechanisms underlying part of its pathophysiology. This section will explore a naturally 
occurring cystitis model in felines and focus its review on experimental models of cystitis 
induced chemically. It is important to note that models of BPS/IC are not limited to what 
will be discussed in this section and exhaustive reviews have been previously published 
(Bjorling, Wang, & Bushman, 2011; Fry et al., 2010; Westropp & Buffington, 2002). 
The natural development of spontaneous LUT symptoms has been documented 
in cats for several decades and is termed feline interstitial cystitis (FIC) (Bjorling et al., 
2011; Lyngset, 1972). Though the primary insult for FIC is not known, the 
pathophysiology has marked similarities to BPS/IC including uroepithelial dysfunction 
and visceral inflammation. Cats with FIC have been shown to have a disruption to the 
epithelial cytoarchitecture that increased diffusion and infiltration of urinary constituents 
(Gao, Buffington, & Au, 1994; Lavelle et al., 2000). Uroepithelial dysfunction in FIC 
further leads to a peripheral upregulation of neuropeptides and inflammatory mediators 
that alter bladder afferent soma size and increase input to the central nervous system 
(CNS) (Birder et al., 2010). As previously discussed, the alterations to central and 
peripheral reactivity following uroepithelial dysfunction and/or visceral inflammation 
may promote the development of LUT symptoms that is observed in FIC and, by 
extension, BPS/IC (Birder et al., 2010; Grover et al., 2011; Sant et al., 2007). 
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Despite these pathophysiological similarities, FIC as a model for BPS/IC is 
limited due to its spontaneity and epidemiology. Investigators are practically and 
financially restricted to structural and functional alterations following its spontaneous 
induction and thus inadequately define insults preceding the development of FIC 
(Westropp & Buffington, 2002). Furthermore, unlike BPS/IC, FIC occurs irrespective of 
biological sex (Westropp & Buffington, 2002). While this may be due to a misdiagnosis 
of BPS/IC in males, one cannot discount hormonal differences that may affect LUT 
symptoms in humans (Robinson & Cardozo, 2003; Rohrmann et al., 2007). 
 LUT symptoms have also been induced by an assortment of chemical irritants 
including, but not limited to: hydrochloric acid, acetic acid, protamine sulfate (PS) and 
cyclophosphamide (CYP). The inflammation induced by intravesical instillation of 
irritants like hydrochloric acid and acetic acid help reveal the anatomical, organizational 
and functional alterations attributable to the visceral immune response (Bjorling et al., 
2011). Specifically, the functional and histological features following acid instillation are 
similar to a BPS/IC subset and include urothelial hyperplasia, bladder ulceration, mucosal 
edema, inflammatory cell infiltration and the development of LUT symptoms (Osorio, 
Simckes, & Hellerstein, 1996; Yoshida, Kageyama, Fujino, Nozawa, & Yamada, 2010). 
Though acid instillation allows for a more controlled environment than FIC, the studies 
must be interpreted cautiously as the degree of inflammation resulting from exogenous 
irritants may not be representative of the naturally occurring BPS/IC (Bjorling et al., 
2011). 
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Unlike acid instillation, PS lacks a pervasive inflammatory element but rather 
disrupts uroepithelial barrier function by targeting bladder surface proteoglycans (C. L. 
Parsons, Stauffer, & Schmidt, 1988). Similar to the uroepithelial dysfunction observed in 
FIC, PS instillation is sufficient to induce LUT symptoms (Soler et al., 2008). More 
recently, PS has been used in conjunction with bacterial induced cystitis. Instillation of 
both PS and E. coli lipopolysaccharide to respectively damage the urothelium and induce 
a visceral inflammatory cascade may help clarify the interaction(s) of multiple processes 
underlying LUT symptoms in BPS/IC (Bjorling et al., 2011; Stein, Pham, Ito, & Parsons, 
1996).  
CYP is an antineoplastic prodrug that requires enzymatic activation to release 
phosphoramide mustard and the byproduct acrolein (Emadi, Jones, & Brodsky, 2009; 
Powers & Sladek, 1983). A known adverse toxicity following systemic CYP 
administration is hemorrhagic cystitis (Emadi et al., 2009). Hemorrhagic cystitis arises 
from the bladder mucosal walls contact with acrolein, which increases vascular 
permeability and results in bladder ulceration and hypertrophy (Batista et al., 2006). In 
addition to hemorrhagic cystitis, systemic CYP treatment causes functional and 
histological changes similar to BPS/IC including: mucosal edema, uroepithelial 
dysfunction, inflammatory cell infiltration, afferent nerve hyperexcitability and the 
development of LUT symptoms (M. Boucher et al., 2000; Eichel et al., 2001; Malley & 
Vizzard, 2002; Stewart, 1986; Yoshimura & de Groat, 1999). CYP administration also 
produces behavioral alterations consistent with the development of viscerosomatic pain 
including decreased breathing rate, closing of the eyes and rounded back postures (M. 
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Boucher et al., 2000). While the urinary bladder inflammatory response following 
systemic CYP administration is greater than that observed in BPS/IC, this experimental 
model of cystitis is appealing because of its route of administration (intraperitoneal) and 
the chronicity and reproducibility of histopathological and functional alterations (Bjorling 
et al., 2011). 
1.3. Transforming Growth Factor-beta 
1.3.1. Background 
The transforming growth factor-beta (TGF-β) superfamily is comprised of at 
least 35 pleiotropic proteins belonging to four subfamilies grouped by their sequence 
homology—decapentaplegic-Vg-related (DVR), activin/inhibin, TGF-β sensu stricto and 
other divergent members (Herpin, Lelong, & Favrel, 2004). Even though TGF-β 
superfamily members have distinct expression patterns and regulate a variety of 
functions, they are each translated as a pre-pro-protein that contains a peptide sequence 
signaling to the endoplasmic reticulum, a N-terminal prodomain and a C-terminal mature 
protein (Annes, Munger, & Rifkin, 2003; Herpin et al., 2004). After proteolytic 
processing and posttranslational modifications, the C-terminal fragment is either secreted 
as a mature protein dimer or forms a latent complex by maintaining a noncovalent bond 
to the prodomain (Annes et al., 2003; Herpin et al., 2004).  
The canonical members of TGF-β sensu stricto are one such proprotein to form 
a latent complex. The interactions between the N-terminal prodomain, termed latency 
associated peptide (LAP), and the mature TGF-β dimer is sufficient to sequester its 
extracellular activity (Shi et al., 2011). Additionally, LAP associates with a latent TGF-β 
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binding protein (LTBP) that regulates TGF-β bioavailability by chaperoning the complex 
to the extracellular matrix (Todorovic et al., 2005). The subsequent activation of latent 
TGF-β in the extracellular matrix via LAP cleavage occurs by protease-dependent or 
protease-independent (protons, integrins, reactive oxygen species, etc.) mechanisms 
(Annes et al., 2003; Barcellos-Hoff & Dix, 1996; Lyons, Keski-Oja, & Moses, 1988; 
Murphy-Ullrich & Poczatek, 2000; van der Flier & Sonnenberg, 2001). 
After its secretion, the mature or activated protein dimers transduce a signal 
through transmembrane Ser-Thr receptor kinases (Herpin et al., 2004). The TGF-β family 
of receptors is comprised of type I and type II receptors. Type II receptors selectively 
bind their respective ligands to define part of the specificity of signal transduction 
(Herpin et al., 2004). Ligand binding can either be “sequential” or “cooperative” and may 
involve an accessory receptor (type III) to enhance ligand presentation (Massague, 1998). 
Following receptor-ligand interaction, the type II receptor forms a heterotetrameric 
complex with the type I receptor to transphosphorylate residues of the Gly-Ser (GS) box 
(Massague, 1998). The activated type I receptors then phosphorylate Smad-dependent or 
Smad-independent substrates to regulate the transcription of target genes (Derynck & 
Zhang, 2003). 
Smad proteins exist in three families: receptor-activated, common mediator and 
inhibitory. Receptor-activated (R-) Smads dock onto type I receptors and are 
phosphorylated on distal serine residues following receptor activation (Derynck & Zhang, 
2003). Phosphorylated R-Smads dissociate from the receptor and interact with common 
mediator Smad4 (Derynck & Zhang, 2003). The oligomeric R-Smad/Smad4 complex 
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then translocates to the nucleus where it alters the transcription of target genes (Derynck 
& Zhang, 2003). Type I receptors not only function through Smad signaling but may also 
directly activate Smad-independent pathways such as TGF-β-activated kinase 1 (TAK1), 
Ras, nuclear factor-κB (NF-κB) and the mitogen-activated protein kinase (MAPK) 
subfamily members (Engel, McDonnell, Law, & Moses, 1999; Freudlsperger et al., 2013; 
M. K. Lee et al., 2007; Moustakas & Heldin, 2005; Yamaguchi et al., 1995; L. Yu, 
Hebert, & Zhang, 2002). The variety of direct and context-dependent downstream 
signaling pathways preserves the multifunctional role(s) of TGF-β superfamily ligands 
while providing the specificity required to control distinct target genes. 
1.3.2. Immune Response 
The canonical members of TGF-β sensu stricto maintain immunological 
function by regulating the initiation and resolution of the immune response and a 
comprehensive review has been previously published (M. O. Li, Wan, Sanjabi, 
Robertson, & Flavell, 2006). Briefly, activated TGF-β at the site of injury may initiate a 
proinflammatory milieu characterized by matrix remodeling and the recruitment and 
activation of leukocytes (Ashcroft, 1999; M. O. Li et al., 2006). TGF-β may then aid in 
resolving the primary immune response and support a milieu for tissue repair and 
immunological memory to progress by suppressing the proliferation, differentiation and 
survival of a subset of lymphocytes (M. O. Li et al., 2006). 
 To initiate an immune response, TGF-β may mobilize monocytes, mast cells and 
granulocytes to the site of injury and influence their adhesion to the extracellular matrix 
(Gruber, Marchese, & Kew, 1994; M. O. Li et al., 2006; Reibman et al., 1991; van Royen 
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et al., 2002). While TGF-β may also recruit monocyte-derived macrophages, their 
activation and function is typically inhibited to help resolve the immune response 
(Ashcroft, 1999; S. Chen et al., 2005; Werner et al., 2000). Since immune cells continue 
to infiltrate the site of injury, the extracellular matrix undergoes pathological remodeling 
characterized by protease secretion and matrix degradation (Sorokin, 2010). TGF-β 
supports the remediation and repair of these tissues by increasing the deposition of matrix 
proteins and inhibiting protease activation (Leask & Abraham, 2004).  
To sustain the resolution of the immune response, TGF-β may regulate T cell 
proliferation, differentiation and survival (Gorelik & Flavell, 2002). TGF-β promotes T 
cell growth arrest by suppressing interleukin 2 in areas of subthreshold antigen 
presentation (Kehrl et al., 1986; M. O. Li et al., 2006). During the polarizing conditions 
of the immune response, TGF-β maintains peripheral immunological tolerance by 
inducing the transcription factor FoxP3 to promote CD4+CD25+ T cell differentiation to 
regulatory T cells (M. O. Li et al., 2006; Marie, Letterio, Gavin, & Rudensky, 2005). 
CD4+ T cell differentiation to the T helper (Th) 1 and Th2 cell lineages, however, is 
inhibited by TGF-β mediated repression of the transcription factors T-bet and GATA-3, 
respectively (Gorelik, Fields, & Flavell, 2000; Gorelik & Flavell, 2002). In addition to its 
effects on CD4+ T cells, TGF-β may also attenuate the cytotoxicity of CD8+ T cells by 
inhibiting its cytolytic genes (Thomas & Massague, 2005).  
TGF-β not only stabilizes T cell expression and function to resolve the immune 
response, but also regulates B cell proliferation, survival and development (Lebman & 
Edmiston, 1999). TGF-β inhibits both the proliferation and cell cycle progression of B 
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cells through Smad-dependent or Smad-independent pathways (Heldin, Landstrom, & 
Moustakas, 2009; Kee, Rivera, & Murre, 2001; M. O. Li et al., 2006; Smeland et al., 
1987). TGF-β utilizes comparable B cell growth arrest pathways, as well as a distinct 
Smad-independent pathway, to induce the apoptosis of B cells (M. O. Li et al., 2006; 
Perlman, Schiemann, Brooks, Lodish, & Weinberg, 2001). Lastly, TGF-β may regulate 
the maturation and activation of B cells through its induction of isotype switching, 
suppression of B cell antigen receptor signaling and inhibition of immunoglobulin 
secretion (Cazac & Roes, 2000; Kehrl, Thevenin, Rieckmann, & Fauci, 1991; M. O. Li et 
al., 2006). 
1.3.3. Nociception 
The members of TGF-β sensu stricto contribute to both the peripheral and 
central processing of noxious stimuli. TGF-β1 and TGF-β2 have been demonstrated to 
increase de novo neuropeptide synthesis in the DRG that may directly sensitize primary 
afferent nociceptors (Chalazonitis, Kalberg, Twardzik, Morrison, & Kessler, 1992; 
Levine, Fields, & Basbaum, 1993). TGF-β may also influence DRG excitability by 
regulating several ion channels including the voltage-gated potassium (Kv) channel and 
TRPV-1. Application of recombinant TGF-β1 in vitro has been demonstrated to 
downregulate KCNA4 gene expression and decrease A-type Kv currents in primary DRG 
cultures (Zhu et al., 2012). Additionally, TGF-β1 Smad-independent signaling may 
phosphorylate TRPV-1 on Thr residues and potentiate capsaicin-evoked calcium influx in 
the DRG (Utreras et al., 2012; Utreras et al., 2013). The subsequent prolonged 
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depolarization and an impaired repolarization may lead to an amplification of nociceptive 
transmission and CNS input. 
Unlike its role in the periphery, TGF-β in the CNS appears to be neuroprotective 
by regulating neuronal and nonneuronal response to inflammatory injury (Lantero, 
Tramullas, Diaz, & Hurle, 2012). Nonneuronal glial cells have recently been recognized 
to enhance the proinflammatory milieu and facilitate the central processing of 
nociception (O'Callaghan & Miller, 2010).  Activated TGF-β in the CNS may inhibit the 
proliferation and activation of these spinal glial cells to attenuate the induction of 
neuropathic pain (Abutbul et al., 2012; Echeverry et al., 2009; Xiao, Bai, Zhang, & Link, 
1997). TGF-β may further reduce excitatory synaptic transmission of second-order 
neurons by directly suppressing the proinflammatory milieu in the spinal cord (Echeverry 
et al., 2009). As a result of its biphasic and modulatory role in the peripheral and central 
transmission of nociception, TGF-β appears to have a profound impact on the perception 
of pain and may initiate, in part, pathological pain syndromes. 
1.3.4. Role(s) in Cystitis 
 TGF-β ligands and its cognate receptors are expressed at low, basal levels in rat 
urinary bladder tissues (Gonzalez, Girard, & Vizzard, 2013). Following chemically 
(CYP)-induced cystitis of varying durations, TGF-β ligand and receptor expression 
appears to display a time- and tissue-dependent regulation. TGF-β exhibits a delayed, but 
sustained, increase in urinary bladder gene and protein expression 8-48 h after CYP 
treatment (Gonzalez et al., 2013; Tyagi et al., 2009; Zhang & Qiao, 2012). Furthermore, 
urinary excretion of active and latent TGF-β1 is increased up to 100-fold 24 h after acute 
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CYP treatment (Tyagi et al., 2009). The aforementioned regulation of TGF-β gene and 
protein expression has been suggested to be more pronounced in the afferent limb of the 
micturition reflex suggesting a possible role in the development of LUT symptoms 
(Gonzalez et al., 2013). Its role in micturition reflex dysfunction was confirmed with 
cystitis and the pharmacological inhibition of aberrant TGF-β signaling. SB505124, a 
potent inhibitor of TGF-β type I receptor kinase activity, decreased urinary frequency and 
increased bladder capacity, void volume and intercontraction intervals 48 h following 
CYP-induced cystitis (Gonzalez et al., 2013). These studies raise the possibility of 
targeting TGF-β at the level of the urinary bladder to alleviate voiding dysfunction with 
cystitis. 
1.4. ATP and Purinergic Receptor/Signaling 
1.4.1. Background 
The urothelium releases neuroactive transmitters, in particular ATP, from its 
apical and basolateral surfaces in response to physical and chemical stimuli (L. Birder & 
K. E. Andersson, 2013; Burnstock, 2014). ATP and other nucleotides derived from the 
urothelium can be released through several mechanisms that include transporters, ion 
channels or vesicular exocytosis (Bodin & Burnstock, 2001; Wang et al., 2005). 
Extracellular ATP that is not degraded by ectonucleotidases or exonucleotidases is then 
able to stimulate autocrine or paracrine pathways that may aid in the sensory transduction 
to the CNS (Schwiebert & Zsembery, 2003). The transduction pathways within the 
urinary bladder are affected by receptor subtype expression and their proximity to the 
urothelium. The tissues and cell types that may contribute to purinergic or pyrimidinergic 
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signaling include the urothelium (Dunning-Davies, Fry, Mansour, & Ferguson, 2013; W. 
Yu, Zacharia, Jackson, & Apodaca, 2006), ICC (Y. Li et al., 2013), smooth muscle cells 
(Gopalakrishnan et al., 2002; Yang et al., 2000) and suburothelial nerve fibers (L. Birder 
& K. E. Andersson, 2013; Gonzalez, Merrill, & Vizzard, 2014). 
1.4.2. P2X and P2Y Receptor Expression and Function in the LUT 
P2-purinoceptors are classified as ligand-gated ion channels, P2X, or G-protein 
coupled receptors, P2Y (Fredholm et al., 1994). There are currently seven P2X subunits 
(P2X1-7) that may arrange as heteromeric or homomeric ligand-gated ion channels and 
eight metabotropic P2Y subunits (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, 
P2Y14) that may couple to Gs, Gi or Gq (Abbracchio et al., 2006; North, 2002). While 
the kinetics and tissue distribution of each P2-purinoceptor differs, there is substantial 
evidence that many of these subunits are functionally expressed throughout the urinary 
bladder urothelium, lamina propria and detrusor smooth muscle. 
 The distribution of P2X and P2Y receptors in the urothelium has been described 
in multiple species, including rodents, felines and humans. P2X2 and P2X4-7 receptor 
immunoreactivity (IR) was detected in the rodent urothelium, whereas, positive IR was 
detected for P2X1-7 in the feline urothelium (Table 1) (Birder et al., 2004; H. Y. Lee, 
Bardini, & Burnstock, 2000; Vial & Evans, 2000). In the human bladder urothelium, 
glycosylated P2X2 and P2X3 transcript and protein expression has also been detected 
(Tempest et al., 2004). There appears to be less diversity in the uroepithelial distribution 
of P2Y receptors where P2Y2 and P2Y4 transcript and protein expression has been 
demonstrated in cultured rat uroepithelial cells (Chopra et al., 2008). Additionally, in the 
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human uroepithelial cell line, UROtsa, P2Y1, P2Y2 and P2Y11 transcript expression was 
detected (Save & Persson, 2010). 
 Nucleotides and their metabolites seem to have an intricate role in ATP release 
and P2 receptor signaling in the urothelium. More specifically, adenosine diphosphate 
(ADP) has been demonstrated to evoke ATP release from the urothelium, whereas 
adenosine exerts inhibition on ATP release via A1 receptors (Dunning-Davies et al., 
2013; Mansfield & Hughes, 2014). The diverse expression of purine and pyrimidine 
receptor subtypes in the urothelium also allows for distinct signal transduction (Chopra et 
al., 2008; H. Y. Lee et al., 2000; Tempest et al., 2004). The activation of P2Y, but not 
P2X, receptors on the urothelium evokes ATP release suggesting urothelial P2Y 
receptors may contribute to purinergic neurotransmission (Chopra et al., 2008; G. Sui et 
al., 2014). 
The urinary bladder lamina propria is deep to the mucosal basement membrane 
and includes loose connective tissue, vasculature, lymphatics, nerves and interstitial cells 
(Andersson & McCloskey, 2013). A population of interstitial cells in the lamina propria 
(ICC-LP) also express P2X3, P2Y2, P2Y4 and P2Y6 receptors and are proposed to form 
a functional syncytium with smooth muscle cells (Table 1) (Drumm, Koh, Andersson, & 
Ward, 2014; G. P. Sui, Wu, & Fry, 2006). In response to ATP, ICC-LP generate P2Y-
dependent intracellular calcium transients followed by inward currents (C. Wu, Sui, & 
Fry, 2004). These ATP-generated transients may then propagate to smooth muscle cells 
via gap junctions to alter contractility (Drumm et al., 2014). Although the mechanism 
coupling ICC-LP to sensory activity is not yet known, the localization of ICC-LP and its 
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responsiveness to ATP suggest they may have a regulatory role in the afferent limb of the 
micturition reflex (C. Wu et al., 2004). In addition to the functional syncytium with ICC-
LP, urinary bladder smooth muscle cells express P2X1–P2X6 and P2Y receptors (Dutton, 
Hansen, Balcar, Barden, & Bennett, 1999). P2X1 receptors have received much of the 
focus on bladder contractility due to their contributions to nerve evoked bladder 
contractions (Vial & Evans, 2000). More recently, P2Y6 receptors have also been 
demonstrated to modulate bladder smooth muscle tone and augment P2X-mediated 
bladder contraction (W. Yu, Sun, Robson, & Hill, 2013). 
Afferent (and efferent) nerves terminating in the urothelium, lamina propria and 
detrusor smooth muscle have received much of the attention in characterizing P2-
purinoceptor distribution (Table 1). While the transcript and protein expression of all 
seven P2X subunits (P2X1-7) have been detected in the rodent DRG, there appears to be 
a differential distribution of P2X2 and P2X3 depending on spinal cord level (X. Chen & 
Gebhart, 2010; Ruan et al., 2005; Xiang, Bo, & Burnstock, 1998). P2X2 mRNA has been 
detected in both thoracolumbar and lumbosacral urinary bladder afferent neurons, but 
transcripts at the thoracolumbar level appear to be co-expressed with P2X3 (X. Chen & 
Gebhart, 2010). P2X3 transcripts, on the other hand, appear to be restricted to small- and 
medium-diameter afferent neurons and have a greater frequency of expression in 
thoracolumbar than lumbosacral neurons (Bradbury, Burnstock, & McMahon, 1998; X. 
Chen & Gebhart, 2010; Ruan et al., 2005). Similar to the urothelium, there appears to be 
less diversity in the distribution of P2Y receptors in DRG neurons. P2Y1, P2Y2 and 
P2Y4 transcript expression has been detected in rodent DRG neurons with P2Y1 
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restricted to small-diameter neurons and P2Y4 to medium- and large-diameter neurons 
(Ruan & Burnstock, 2003). P2Y2 and P2Y4, in particular, have been detected in 
thoracolumbar and lumbosacral bladder afferent neurons by retrograde labeling (X. Chen, 
Molliver, & Gebhart, 2010).  
Although not yet conclusive, the proximity of afferent nerve terminals to the 
urothelium indicates a role in purinergic sensory transduction. Previous studies have 
established the functional contributions of P2X2 and P2X3 receptors to the afferent limb 
of the micturition reflex (Kaan et al., 2010). P2X3 receptor-mediated mechanisms have 
been demonstrated to contribute to both nociceptive and non-nociceptive 
mechanosensory transduction in the bladder (Rong, Spyer, & Burnstock, 2002). 
Furthermore, mice lacking P2X2/P2X3 receptor subunits exhibit decreased urinary 
bladder reflexes and decreased pelvic afferent nerve activity in response to bladder 
distention (Cockayne et al., 2005). The functional contributions to bladder sensory 
neuron sensitization have also been demonstrated with P2Y2 receptors (X. Chen et al., 
2010). P2Y2 receptor activation was able to facilitate P2X2 and P2X3 evoked currents 
and increase bladder neuron excitability (X. Chen et al., 2010). 
Table 1: Purinergic receptors/channels in the LUT 
Purinergic receptors are functionally distributed throughout the tissues and cell types of the urinary bladder. 
Abbreviations: ADP, adenosine diphosphate; ATP, adenosine triphosphate; BAN, bladder afferent nerve; 
Det, detrusor; ICC, interstitial cell of Cajal; P, purinergic; UC, urothelial cell; UDP, uridine diphosphate; 
UTP, uridine triphosphate. *Species differences. Reprinted by permission from Macmillan Publishers Ltd: 
Nature Reviews Urology, Merrill, L., Gonzalez, E.J., Girard, B.M., Vizzard, M.A..  TRP channels and 














LUT distribution LUT function 
P2X (1-7) ATP UC, Det, ICC, BAN* Visceral 
mechanosensation, 
BAN sensitivity 
P2Y (1, 2, 4 and 6) Nucleotides 
(ATP; ADP; 
UTP; UDP) 
UC, Det, ICC, BAN* Visceral 
mechanosensation, 
BAN sensitivity 
P1 Adenosine UC, Det, SubU* Voiding threshold 
 
1.4.3. Role(s) in Cystitis 
 Of the seven P2X subunits, P2X2 and P2X3 have been suggested to be involved 
in the sensitization of urinary bladder sensory transduction with cystitis. Specifically, 
P2X2 and P2X3 protein expression in the human bladder urothelium has been 
demonstrated to increase in IC (Tempest et al., 2004). Likewise, P2X2 transcript 
expression was increased in mouse thoracolumbar DRG neurons with cyclophosphamide 
(CYP)-induced cystitis (X. Chen & Gebhart, 2010). Inhibition of P2X3 or P2X2/3 
receptors with A-317491 following CYP-induced cystitis reduced non-voiding 
contractions and residual urine volume and increased intermicturition intervals 
suggesting a role for purinergic signaling in bladder hyperreflexia with cystitis (Ito, 
Iwami, Katsura, & Ikeda, 2008).  
 CYP-induced cystitis has also been demonstrated to increase peak urinary 
bladder afferent nerve activity that was significantly decreased following P2X receptor 
antagonist (TNP-ATP or PPADS) instillation (Y. Yu & de Groat, 2008). The significance 
of P2X3 specifically in bladder afferent nerve sensitization was demonstrated with P2X3-
null mice and its attenuation of P2X agonist (ATP or α,β-meATP) induced afferent nerve 
excitation (Vlaskovska et al., 2001). Additionally, following CYP-induced cystitis, 
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thoracolumbar rat DRG neurons increased homomeric P2X3 current, whereas, 
lumbosacral rat DRG neurons increased heteromeric P2X2/3 current (Dang, Lamb, 
Cohen, Bielefeldt, & Gebhart, 2008). While CYP-treated urinary bladder neurons exhibit 
increased responsiveness to purinergic agonist application, the changes in P2X subtypes 
do not appear to be conserved across species (X. Chen & Gebhart, 2010; Dang et al., 
2008). For instance, homomeric P2X2 currents not seen in rat DRG neurons increased in 
mouse lumbosacral DRG neurons (X. Chen & Gebhart, 2010). 
Although the role of P2Y receptors in urinary bladder sensory transduction is 
still being resolved, P2Y2 has been implicated in bladder afferent hyperexcitability. UTP, 
a P2Y2 and P2Y4 agonist, application depolarized the resting membrane potential and 
increased action potential frequency in bladder afferent neurons (X. Chen et al., 2010). 
UTP application also potentiated homomeric P2X2 current in wildtype (WT) but not 
P2Y2-null mice suggesting P2Y2 may contribute to P2X-mediated afferent nerve 
sensitization that was observed with cystitis (X. Chen et al., 2010). 
1.4.4. Role(s) in Human Bladder Dysfunction 
Increased levels of urinary ATP have been demonstrated in patients with IC 
(Sun, Keay, De Deyne, & Chai, 2001), OAB (Silva-Ramos et al., 2013) and other 
functional disorders of the urinary bladder (Burnstock, 2014). Primary bladder urothelial 
cells taken from these patients also exhibit increased ATP release in response to 
mechanical stretch (Sun et al., 2001), hypotonic stress (Sun & Chai, 2006) or electrical 
field stimulation (Kumar, Chapple, Rosario, Tophill, & Chess-Williams, 2010). In 
addition to increased urothelial-derived ATP release, changes in P2X receptor subtype 
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expression within various bladder tissues have also been demonstrated in patients with IC 
(Tempest et al., 2004), detrusor instability (O'Reilly et al., 2002) or bladder outlet 
obstruction (O'Reilly et al., 2001). The established role(s) of purinergic signaling in 
bladder sensation suggest that these neurochemical alterations may contribute to the 
development of LUT symptoms in these patients. Thus, an alternative therapeutic 
approach to improve bladder function may be to target purinergic neurotransmission 
within sensory components of the micturition reflex (Burnstock, 2011). 
1.5. Project Goals and Hypotheses 
BPS/IC is a major unresolved health concern in the United States with an 
economic burden approaching $500 million per year in lost productivity and health care. 
BPS/IC is defined by at least six weeks of dysuric symptoms and unpleasant sensations 
(visceral pain and discomfort) perceived to be related to the urinary bladder and in the 
absence of other clinically identifiable sources. Despite advancements in our 
understanding of the biological mechanisms of these pain syndromes, current 
pharmaceutical and behavioral therapies are ineffective and fail to completely resolve 
pathological symptoms. There is, therefore, a critical need to understand mechanistically 
the neurochemical, functional and organizational alterations underlying BPS/IC and how 
this translates into the constellation of clinical symptoms. In the absence of such 
knowledge and effective management, BPS/IC continues to negatively impact the 
economy and those suffering from BPS/IC continue to have physical and psychological 
health dysfunction.  
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Our long-term research goal is to develop successful therapeutic interventions in 
the treatment of BPS/IC. The objective of this dissertation is to identify and characterize 
a novel neurochemical alteration in the micturition reflex pathway and to determine its 
functional role in modulating micturition reflexes. Our central hypothesis is that the 
pleiotropic protein, TGF-β, and its cognate receptors contribute to afferent nerve 
hyperexcitability that may facilitate increased voiding frequency in an experimental 
cystitis model of BPS/IC. Identifying novel components of the urinary bladder 
inflammatory response underlying dysfunction provides a basis for eventual preclinical 
and clinical trials. 
In Chapter 2 of this dissertation we explored the functional expression of TGF-β 
ligands and receptors in the inflamed urinary bladder. We hypothesized that aberrant 
expression will compartmentalize to distinct tissues to reflect the inflammatory state of 
the urinary bladder and contribute to bladder dysfunction. In Chapter 3 of this dissertation 
we explored the sensory components of the urinary bladder that may underlie the 
pathophysiology of aberrant TGF-β activation. We hypothesized that TGF-β1 will 
contribute to bladder afferent nerve excitability through enhanced ATP release from the 
urothelium and purinoceptor activation. At the conclusion of these studies, we will have 
characterized TGF-β ligand and receptor lower urinary tract expression and provided 
evidence for a role of TGF-β signaling in bladder dysfunction. These studies will not only 
increase our understanding of functional disorders and visceral pain, but also have the 
potential to improve the health of those suffering from inflammation-associated bladder 
syndromes.  
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Abstract 
Numerous proinflammatory cytokines have been implicated in the reorganization of 
lower urinary tract function following cyclophosphamide (CYP)-induced cystitis.  The 
present study investigated the functional profile of three pleiotropic transforming growth 
factor-beta (TGF-β) isoforms and receptor (TβR) variants in the normal and inflamed 
(CYP-induced cystitis) rat urinary bladder.  Our findings indicate that TGF-β (1, 2 and 3) 
and TβR (1, 2 and 3) transcript and protein expression were regulated to varying degrees 
in the urothelium or detrusor smooth muscle following intermediate (48 h; 150 mg/kg, 
i.p.) or chronic (75 mg/kg, i.p.; once every three days for ten days), but not acute (4 h; 
150 mg/kg, i.p.), CYP-induced cystitis.  Conscious, open outlet cystometry was 
performed to determine whether aberrant TGF-β signaling contributes to urinary bladder 
dysfunction following intermediate (48 h) CYP-induced cystitis.  TβR-1 inhibition with 
SB505124 (5 µM) significantly (p ≤ 0.001) decreased voiding frequency and increased 
bladder capacity (2.5-fold), void volume (2.6-fold) and intercontraction intervals (2.5-
fold) in CYP-treated (48 h) rats. Taken together, these results provide evidence for: (i) the 
involvement of TGF-β in lower urinary tract neuroplasticity following urinary bladder 
inflammation, (ii) a functional role of TGF-β signaling in the afferent limb of the 
micturition reflex and (iii) urinary bladder TβR-1 as a viable target to reduce voiding 
frequency with cystitis. 




   
Introduction 
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is defined by the presence 
of dysuric symptoms and unpleasant sensations (visceral pain and discomfort) perceived 
to be related to the urinary bladder lasting longer than 6 weeks and in the absence of 
other clinically identifiable sources (25).  While the etiology remains unknown, 
overlapping clinical signs and symptoms suggest an involvement of microbial infection 
(14), submucosal immune cell infiltration (10), disrupted urothelial cell permeability (34) 
or inflammation (44) (for review 22).  We propose that micturition dysfunction and 
visceral neurogenic pain associated with IC/BPS are partly mediated by the urinary 
bladder inflammatory response (18, 21, 41).  Several studies have already established the 
role of proinflammatory cytokines and their downstream targets in the organizational (19, 
31) and functional (3, 29) alterations in micturition reflex pathways following chemically 
(cyclophosphamide; CYP)-induced cystitis.  Most recently, the inflammatory mediator, 
TGF-β, has been implicated in the pathogenesis of CYP-induced cystitis (45, 55). 
The TGF-β superfamily is comprised of at least 35 structurally related 
pleiotropic proteins (28).  In addition to classical TGF-β, the superfamily can be 
subdivided into bone morphogenetic proteins (BMPs), activins/inhibins, growth and 
differentiation factors (GDFs), anti-müllerian hormone (AMH) and nodal (for review 30).  
In mammals, the prototypic TGF-β cytokine exists in three isoforms (TGF-β1, TGF-β2 
and TGF-β3) and is synthesized as a 75 kDa homodimeric propeptide, in which the 
mature growth factor is non-covalently bound to a pro-domain (latency-associated 
protein, LAP) (1).  During secretion, covalent interactions between LAP and a 
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glycoprotein, latent TGF-β Binding Protein (LTBP), translocate the latent complex to the 
extracellular matrix where it can be activated through protease-dependent (54) or 
protease-independent (thrombospondins, integrins, reactive oxygen species and protons 
(6, 35, 38, 47)) mechanisms (for review 1).  The destabilization of TGF-β/LAP and 
LAP/LTBP releases an activated TGF-β dimer that forms a heterotetrameric receptor 
complex comprised of transforming growth factor-β type I receptor (TβR-1) and TβR-2.  
Ligand binding can also be enhanced through a third co-receptor (TβR-3) that lacks an 
intracellular signaling domain (52).  To propagate an intracellular signal, intrinsic 
serine/threonine kinase activity of TβR-2 transphosphorylates TβR-1 to initiate receptor 
regulated SMAD-dependent or SMAD-independent transduction pathways (33). 
The maintenance and modulation of TGF-β signaling is essential for epithelial 
cell cycle progression, proliferation and apoptosis (26), as well as immune cell function 
and inflammation (7).  The present study examined the transcriptional and translational 
regulation of TGF-β (1, 2 and 3) and TβR (1, 2 and 3) in the rat urinary bladder 
inflammatory response and the role for TGF-β signaling in urinary bladder dysfunction 
following CYP-induced cystitis.  Cytotoxicity in the urinary bladder accompanying CYP 
metabolism increases urinary bladder permeability (16), urothelial hyperplasia and 
voiding frequency (43), in addition to altering somatic sensitivity (23, 24), neurochemical 
(48, 50) and electrophysiological (53) properties of micturition reflex function.  
Therefore, CYP-induced cystitis permits a controlled, systematic identification of 
inflammatory mediators underlying urinary bladder dysfunction that would otherwise be 
inaccessible with a clinical population (18).  With this in mind, we determined (i) the 
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temporal and tissue (urothelium and detrusor smooth muscle) expression of TGF-β (1, 2 
and 3) and TβR (1, 2 and 3) urinary bladder transcripts following CYP-induced cystitis 
(acute, intermediate or chronic); (ii) the temporal expression of TGF-β (1, 2 and 3) 
urinary bladder protein following CYP-induced cystitis; (iii) the temporal and tissue 
(urothelium and detrusor smooth muscle) expression of TGF-β1 and TβR (1, 2 and 3) 
using immunohistochemistry following CYP-induced cystitis and (iv) the functional 
effects of pharmacological TβR-1 inhibition using conscious, open outlet cystometry 
following intermediate (48 h) CYP-induced cystitis. 
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Materials and Methods 
Animals  
Naïve adult female Wistar rats (200-375 grams) purchased from Charles River 
Laboratories (Wilmington, MA) were housed two per cage and maintained in standard 
laboratory conditions with food and water available ad libitum.  Estrous cycles were not 
determined at any point in these studies.  Experimental procedures were approved by the 
University of Vermont Institutional Animal Care and Use Committee (protocol 08-085) 
and experimentation was in accordance with the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals (8th edition).  
Induction of CYP-induced cystitis  
Female Wistar rats (n=4-8 per condition) received either no treatment, acute 
(150 mg/kg), intermediate (150 mg/kg) or chronic (75 mg/kg) intraperitoneal (i.p.) 
injections of cyclophosphamide (CYP; Sigma Aldrich, St. Louis, MO).  Following CYP 
(150 mg/kg, i.p.) treatment, rats were harvested either 4 (acute) or 48 (intermediate) 
hours (h) post injection (5, 11, 31).  For chronic CYP (75 mg/kg, i.p.) treatment, rats 
received injections every third day for ten days and tissues were harvested on the tenth 
day (5, 11, 31). 
Antibodies  
Polyclonal primary antibodies were purchased from Santa Cruz Biotechnology, 
Inc. (Dallas, TX): rabbit anti-TGF-β1 (sc-146, 1:1000), rabbit anti-TβR-1 (sc-398, 
1:5000), rabbit anti-TβR-2 (sc-220, 1:2000), goat anti-TβR-3 (sc-6199, 1:1000).  
Secondary antibodies were purchased from Jackson Immuno Research Labs (West 
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Grove, PA): Cy3 AffiniPure Goat Anti-Rabbit IgG (H+L) (111-165-144, 1:500) and Cy3 
AffiniPure Donkey Anti-Goat IgG (H+L) (705-166-147, 1:500). Primary antibodies were 
diluted in 0.1 M phosphate buffered saline (PBS) containing either 1% goat or donkey 
serum.  
Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)  
Female Wistar rats (n=5-7 per condition) were anaesthetized with 2% isoflurane 
and urinary bladders were harvested under RNase-free conditions following a 
thoracotomy.  Components of the urinary bladder (urothelium and detrusor smooth 
muscle) were separated as previously described (9, 32).  For transcript analyses, the term 
urothelium refers to both the urothelial cell layers (basal, intermediate and apical) and 
accompanying suburothelial structures.  Total RNA was extracted from urothelium and 
detrusor smooth muscle using STAT-60 total RNA/mRNA isolation reagent (Tel-Test 
‘B’, Friendswood, TX) and complementary DNA (cDNA) was synthesized using random 
hexamer and oligo dT primers with M-MLV reverse transcriptase (Promega Corp, 
Madison, WI) (20).  cDNA templates were assayed using HotStart-IT SYBR Green 
qPCR Master Mix (USB Corporation, Cleveland, Ohio) containing 5 mM MgCl2, 0.4 
mM dATP, dGTP, dCTP and dTTP, HotStart-IT Taq DNA polymerase and 300 nM of 
each primer (Table 1) in a final 25 µL reaction volume (3, 20, 32).  qRT-PCR was 
performed on an Applied Biosystems 7500 Fast real-time PCR system (Foster City, CA) 
using previously defined conditions (3, 20, 32).  Amplicons were subjected to a SYBR 
Green I melting curve analysis by ramping the reaction temperature from 60˚C to 95˚C.  
A single hyperchromic effect was observed under these dissociation conditions 
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demonstrating amplification of a specific product free of primer-dimers or other 
contaminants. 
Analysis: Data were analyzed at the termination of each assay using the 
Sequence Detection Software (version 1.3.1; Applied Biosystems, Norwalk, CT).  A 
standard curve was constructed by amplification of serially diluted plasmids containing 
the target sequence. The increase in SYBR Green I fluorescence intensity (ΔRn) was 
plotted as a function of cycle number and the threshold cycle (CT) was the amplification 
cycle at which ΔRn intersects baseline (3, 20, 32).  qRT-PCR data are expressed as 
relative quantity of the gene of interest normalized to the relative quantity of the 
ribosomal reference gene, L32 (19). 
Enzyme-Linked Immunosorbent Assays (ELISAs) 
Female Wistar rats (n=8 per condition) underwent the aforementioned CYP 
treatment and tissue harvest.  Individual whole urinary bladders were weighed and 
solubilized for immunoassays in tissue protein extraction (Pierce Biotechnology, 
Woburn, MA) solution, a mild zwitterionic dialyzable detergent, supplemented with a 
complete protease inhibitor cocktail (Roche, Indianapolis, IN) (36).  Tissue was 
homogenized using a Kinematica Polytron homogenizer (Fischer Scientific, Pittsburgh, 
PA) and centrifuged (3,000 rpm at 10°C for 10 min).  Supernatant was removed and 
protein was quantified according to manufacturer instructions using a Coomassie Plus 
Protein Assay Kit (Pierce Biotechnology). 
Ninety-six (96)-well microtiter plates (R&D Systems, Minneapolis, MN) were 
coated overnight with a capture antibody specific to the analyte (DuoSet Development 
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Systems, R&D Systems).  Plates were washed (1X PBS with 0.05% Tween20), blocked 
(1X PBS with 5% Tween20) and then standards and samples were added in duplicate.  
Standards provided by the manufacturer consisted of a seven point standard curve (r2= 
0.989-0.997) in Reagent Diluent (1% BSA in PBS) beginning at 2,000 pg/mL.  Following 
a 2 h incubation, standards and samples were vigorously washed three times (3x) and a 
biotinylated detection antibody specific to the analyte was added and allowed to incubate 
for 2 h.  Plates were washed (3x) and a detection reagent (streptavidin-horseradish 
peroxidase) was added and incubated for 20 min.  Plates were washed (3x) and a 
substrate solution (hydrogen peroxide and tetramethylbenzidine) was added. Following 
20 min incubation, reactions were terminated with 2N sulfuric acid and the optical 
density was read at 450 nm and 570 nm.   
Analysis: Absorbance values were corrected for optical imperfections by 
subtracting readings at 570 nm (49).  Samples were diluted to bring absorbance values 
onto the linear portion of the standard curve. Samples did not fall below the minimum 
detection limits of the assay.  Curve fitting of standards and sample were performed using 
least-squares fit regression analysis (49). 
Immunohistochemistry 
Female Wistar rats (n=4 per condition) underwent the aforementioned CYP 
treatment and tissue harvest.  Urinary bladder tissue was immediately allowed to incubate 
in 4% paraformaldehyde for 24 h at 4°C and was then transferred to 30% sucrose in 0.1 
M PBS overnight at 4°C.  Tissue was embedded in optimal cutting temperature 
compound (Tissue-Tek, Batavia, IL), sectioned at 20 µm and mounted on 0.5% gel-
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coated slides (5, 9, 11).  Sections were incubated overnight in polyclonal primary 
antibody (rabbit anti-TGF-β1, rabbit anti-TβR-1, rabbit anti-TβR-2 and goat anti-TβR-3), 
washed (3 x 10 min) and then incubated in Cyanine 3 (Cy3) AffiniPure conjugated 
secondary antibody for 2 h.  Following washing (3 x 10 min), slides were mounted with 
an anti-fading media (Citifluor, Fischer Scientific) and coverslipped.   
Visualization and semi-quantitative analysis: Immunoreactivity was captured 
using an Olympus fluorescent photomicroscope with a charge-coupled device (CCD) 
camera (MagnaFire SP, Optical Analysis, Nashua, NH) and LG-3 frame grabber (Scion, 
Frederick, MD).  Each experimental series was processed on the same day with exposure 
time, brightness and contrast held constant throughout image acquisition (5, 9).  To 
visualize Cy3, the filter was set with an excitation range of 560-569 nm and an emission 
range of 610-655 nm (5, 9).  Images (6 per animal) were acquired, saved as 24-bit RGB 
tagged image file format and imported into MetaMorph Image Analysis Software 
(v4.5r4, Microscope Imaging Center, Downingtown, PA) (5, 9).   
The focus of our analyses was on the urothelium and detrusor smooth muscle 
whereas other parts of the lower urinary tract including the suburothelial plexus and 
lumbosacral dorsal root ganglia (DRG) are the focus of a separate study.  A free hand 
drawing tool was used to trace and measure total pixels area in the urothelium (basal, 
intermediate, apical) and excluded any suburothelial structures (11).  For the detrusor 
smooth muscle, six rectangles of fixed dimensions (125 x 125 pixels) were placed 
without overlap according to random x and y coordinates (9, 32).  As previously 
described (9, 32), a threshold encompassing an intensity range of 100-250 grayscale 
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values was applied to the region of interest in the least immunoreactive condition first 
and was maintained throughout the series.  The threshold was adjusted for each 
experimental series with negative controls as a guide for setting background fluorescence 
(9, 32).   
Assessment of immunoreactivity: Immunohistochemistry and evaluation of TGF-
β1 and TβR (1, 2 and 3) immunoreactivity in urothelium or detrusor smooth muscle were 
performed on control and experimental tissues simultaneously to reduce the incidence of 
staining variation that can occur between tissues processed on different days (5, 9, 11). 
Staining in experimental tissue was compared with that in experiment-matched negative 
controls. Negative controls following the same experimental procedures were processed 
in the absence of a polyclonal primary antibody to assess specificity and background 
staining.  In the absence of primary antibody, positive immunoreactivity was not 
observed (data not shown).  Immunoreactivity was considered positive only when 
intensity measurements of the target exceeded the established threshold.  Percent 
immunoreactivity above threshold as a function of total area selected was calculated and 
reported.  For the detrusor smooth muscle, percent target expression above threshold was 
averaged across the six regions. 
Cystometry 
Intravesical Catheter Implant: A dorsal (below scruff of the neck) incision and 
lower midline abdominal incision was performed under 2% isoflurane using aseptic 
techniques. The end of a polyethylene (PE-50; Clay Adams, Parsippany, NJ) tube was 
flared, tunneled and inserted into the bladder dome.  The proximal end was secured to the 
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dome with a 6-0 nylon purse-string suture whereas the distal end was sealed, coiled and 
stored in a dorsal subcutaneous pouch.  Adult female Wistar rats (n=4-5 per condition) 
recovered for 72 h with post-operative analgesia (Buprenorphine, 0.05 mg/kg, s.c.) being 
maintained for 48 h.  No animals met our exclusion criteria (3, 5). 
Conscious, freely moving cystometry with an open outlet: The dorsal 
subcutaneous polyethylene tubing was externalized under 2% isoflurane and the animal 
was placed unrestrained into a Small Animal Cystometry System (Med Associates, St. 
Albans, VT) recording cage over a scale and pan used to quantify voided volume.    The 
animals were each given a 10 min acclimation period prior to the continuous intravesical 
infusion of 0.9% sodium chloride (NaCl) injection, USP (Baxter, Deerfield, IL) at a rate 
of 10 mL/h.  To avoid micturition variation resulting from circadian rhythms, functional 
tests were conducted at similar times of the day (15).  Each animal was run for at least six 
reproducible micturition cycles (pre-drug baseline) after an initial stabilization period (30 
min).  Intravesical pressure (non-voiding, filling, threshold and peak micturition 
pressures), intercontraction interval and infused and voided volume were recorded for 
each micturition cycle.  Bladder capacity was quantified as the total infused 0.9% NaCl at 
the time micturition commenced (3, 5).  Non-voiding bladder contractions were defined 
as rhythmic intravesical pressure increases 0.69 kilopascals (kPa) above baseline without 
the release of fluid from the urethra and are not reported due to their infrequency in the 
current study (3, 5).   
To determine the role of TGF-β on urinary bladder function in control (no 
inflammation) or CYP-treated rats, we intravesically instilled 1 mL of a TβR-1 small 
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molecule inhibitor, SB505124 (5 µM; R&D Systems), under 2% isoflurane for 30 min 
immediately following the baseline measurements. SB505124 (5 µM) was chosen due to 
its in vitro potency and selectivity for TGF-β activated activin receptor-like kinases 
(ALKs) (12).  Intravesical instillation of 1 mL 0.01% dimethyl sulfoxide (DMSO) in 
0.9% NaCl under 2% isoflurane was used for the vehicle control conditions.  Rats 
remained anesthetized during instillation to suppress the micturition reflex and prevent 
expulsion of SB505124 (5 µM) or 0.01% DMSO (2, 3, 5).  At the conclusion of drug 
instillation, urinary bladder function tests were repeated and ran for at least 6 
reproducible micturition cycles (post-drug).  The animals were euthanized following 
functional testing as described above.  
Materials 
SB505124 (R&D Systems) was reconstituted in DMSO (99.5%) and stored at -
20°C.  Prior to its use, stock solutions were diluted to a working concentration (5 μM) 
with 0.9% NaCl injection, USP (Baxter). 
Statistical Analyses 
All values represent mean ± SEM.  Data were compared with one-way or 
repeated measures analysis of variance (ANOVA) where appropriate.  When F(test 
statistic) exceeded the critical value (p ≤ 0.05), the Bonferroni or Newman-Keuls 
multiple comparisons test was used to compare group means. 
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Results 
TGF-β (1, 2 and 3) and TβR (1, 2 and 3) transcript expression in urothelium and detrusor 
smooth muscle following CYP-induced cystitis. 
The regulation of TGF-β (1, 2 and 3) and TβR (1, 2 and 3) transcripts in 
urothelium and detrusor smooth muscle was examined by qRT-PCR analyses (Figure 1, 
A-F).   
TGF-β1 
TGF-β1 transcript expression significantly increased relative to control in the 
urothelium (p ≤ 0.001) and detrusor smooth muscle (p ≤ 0.01) following intermediate (48 
h) CYP-induced cystitis (Figure 1A).  Significant differences were not observed in 
urothelium or detrusor smooth muscle following acute (4 h) or chronic CYP-induced 
cystitis (Figure 1A).   
TGF-β2 
Basal TGF-β2 transcript expression significantly (p ≤ 0.05) differed between 
urothelium and detrusor smooth muscle under control conditions (Figure 1B).  TGF-β2 
transcript expression in the urothelium significantly increased relative to control 
following intermediate (48 h; p ≤ 0.01) or chronic (p ≤ 0.01) CYP-induced cystitis; 
whereas, no significant differences were observed following acute (4 h) CYP-induced 
cystitis (Figure 1B).  Acute (4 h), intermediate (48 h) or chronic CYP-induced cystitis did 
not significantly regulate TGF-β2 transcript expression in the detrusor smooth muscle 
(Figure 1B).   
TGF-β3 
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TGF-β3 transcript expression significantly increased in the urothelium following 
intermediate (48 h; p ≤ 0.001) or chronic (p ≤ 0.05) CYP-induced cystitis relative to 
control; whereas, no significant differences were observed following acute (4 h) CYP-
induced cystitis (Figure 1C).  Acute (4 h), intermediate (48 h) or chronic CYP-induced 
cystitis did not significantly regulate TGF-β3 transcript expression in the detrusor smooth 
muscle (Figure 1C). 
TβR-1 
TβR-1 transcript expression significantly increased relative to control in the 
urothelium following intermediate (48 h; p ≤ 0.01) or chronic (p ≤ 0.001) CYP-induced 
cystitis (Figure 1D).  In the detrusor smooth muscle, significant increases in TβR-1 
transcript expression were only observed following chronic (p ≤ 0.05) CYP-induced 
cystitis relative to control (Figure 1D).  Significant differences in detrusor smooth muscle 
TβR-1 transcript expression were not observed following acute (4 h) or intermediate (48 
h) CYP-induced cystitis (Figure 1D). 
TβR-2 
Intermediate (48 h) CYP-induced cystitis significantly increased TβR-2 
transcript expression in both the urothelium (p ≤ 0.05) and detrusor smooth muscle (p ≤ 
0.05); whereas, significant transcript increase following chronic CYP-induced cystitis 
was only seen in the urothelium (p ≤ 0.001) (Figure 1E).  Acute (4 h) CYP-induced 
cystitis did not significantly regulate urothelial or detrusor smooth muscle TβR-2 
transcript expression (Figure 1E). 
TβR-3 
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TβR-3 transcript expression significantly increased relative to control in the 
urothelium following intermediate (48 h; p ≤ 0.001) and chronic (p ≤ 0.05) CYP-induced 
cystitis (Figure 1F).  Significant transcript increases were similarly seen in the detrusor 
smooth muscle following intermediate (48 h; p ≤ 0.05) and chronic (p ≤ 0.05) CYP-
induced cystitis (Figure 1F).  Acute (4 h) CYP-induced cystitis did not significantly 
regulate TβR-3 transcript expression in the urothelium or detrusor smooth muscle (Figure 
1F). 
TGF-β (1, 2 and 3) protein expression in whole urinary bladder following CYP-induced 
cystitis. 
The regulation of TGF-β (1, 2 and 3) urinary bladder protein was examined by 
ELISAs (Figure 2, A-C).  The selection of analyte was limited by commercial 
availability.  Intermediate (48 h) CYP-induced cystitis significantly increased urinary 
bladder TGF-β1 (p ≤ 0.001) and TGF-β3 (p ≤ 0.05) protein expression relative to control 
(Figure 2, A and C).  Significant differences relative to control were not observed in 
TGF-β1 and TGF-β3 urinary bladder protein expression following acute (4 h) or chronic 
CYP-induced cystitis (Figure 2, A and C). TGF-β2 urinary bladder protein expression did 
not significantly differ relative to control across acute (4 h), intermediate (48 h) or 
chronic CYP treatments (Figure 2B). 
TGF-β1 and TβR (1, 2 and 3) immunoreactivity (IR) in urothelium and detrusor smooth 
muscle following CYP-induced cystitis.  
Based on the transcriptional and translational expression profiles observed, we 
focused immunostaining on TGF-β1 and TβR variants whose mRNA and protein 
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exhibited tissue and temporal regulation by CYP treatment (Figure 1A, 1D, 1E, 1F and 
Figure 2A).  Regional differences in IR were not observed in the dome, body or neck of 
the rat urinary bladder. 
TGF-β1 
Low-intensity, basal TGF-β1-IR was present in all urothelial layers (basal, 
intermediate and apical) and detrusor smooth muscle of control rat urinary bladders 
(Figure 3, A and E).  Acute (4 h) CYP-induced cystitis revealed no observable 
differences in urothelial or detrusor smooth muscle TGF-β1-IR relative to control (Figure 
3, B and F).  Intermediate (48 h) or chronic CYP-induced cystitis, however, resulted in a 
high-intensity TGF-β1-IR in both the urothelium and detrusor smooth muscle (Figure 3, 
C-D and G-H).  Semi-quantitative analyses revealed a significant suprathreshold increase 
relative to control in the urothelium following intermediate (48 h; p ≤ 0.001) or chronic 
(p ≤ 0.001) CYP-induced cystitis (Figure 3I).  Similarly, semi-quantitative analyses in the 
detrusor smooth muscle revealed a significant suprathreshold increase relative to control 
following intermediate (48 h; p ≤ 0.01) or chronic (p ≤ 0.01) CYP-induced cystitis 
(Figure 3J).   
TβR-1 
Low-intensity, basal TβR-1-IR was present in all urothelial layers (basal, 
intermediate and apical) and detrusor smooth muscle of control rat urinary bladders 
(Figure 4, A and E).  Acute (4 h) CYP-induced cystitis resulted in moderate urothelial IR 
relative to control, whereas intermediate (48 h) or chronic CYP-induced cystitis resulted 
in a high-intensity urothelial TβR-1-IR (Figure 4, B-D).  Semi-quantitative analyses 
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revealed a significant suprathreshold increase relative to control in the urothelium 
following intermediate (48 h; p ≤ 0.001) or chronic (p ≤ 0.01) CYP-induced cystitis 
(Figure 4I).  There were no observable differences in detrusor smooth muscle TβR-1-IR 
following acute (4 h) CYP-induced cystitis, while intermediate (48 h) or chronic CYP-
induced cystitis resulted in moderate IR relative to control (Figure 4, F-H).  Semi-
quantitative analyses revealed an emerging trend of robust suprathreshold IR following 
intermediate (48 h) or chronic CYP-induced cystitis (Figure 4J). 
TβR-2 
Low-intensity, basal TβR-2-IR was present in all urothelial layers (basal, 
intermediate and apical) and detrusor smooth muscle of control rat urinary bladders 
(Figure 5, A and E).  Acute (4 h) CYP-induced cystitis resulted in moderate urothelial 
and detrusor smooth muscle IR relative to control, while intermediate (48 h) or chronic 
CYP-induced cystitis resulted in a high-intensity TβR-2-IR (Figure 5, B-D and F-H).  
Semi-quantitative analyses revealed a significant suprathreshold increase relative to 
control in the urothelium following intermediate (48 h; p ≤ 0.001) or chronic (p ≤ 0.01) 
CYP-induced cystitis (Figure 5I).  Similarly, semi-quantitative analyses in the detrusor 
smooth muscle revealed a significant suprathreshold increase relative to control following 
intermediate (48 h; p ≤ 0.001) or chronic (p ≤ 0.01) CYP-induced cystitis (Figure 5J). 
TβR-3 
Low-intensity, basal TβR-3-IR was present in the detrusor smooth muscle of 
control rat urinary bladders (Figure 6A).  Acute (4 h) CYP-induced cystitis resulted in 
moderate IR relative to control, while intermediate (48 h) or chronic CYP-induced 
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cystitis resulted in a high-intensity detrusor smooth muscle TβR-3-IR (Figure 6, B-D).  
Semi-quantitative analyses revealed a significant suprathreshold increase relative to 
control in the detrusor smooth muscle following intermediate (48 h; p ≤ 0.01) or chronic 
(p ≤ 0.01) CYP-induced cystitis (Figure 6E).  TβR-3-IR was not present in the urothelium 
following any control or CYP treatment paradigm (data not shown). 
Urinary bladder function following TβR-1 inhibition in control (no inflammation) or 
intermediate (48 h) CYP-induced cystitis rats. 
Urinary bladder function was determined using open outlet, continuous 
cystometry in conscious, freely moving control or intermediate (48 h) CYP-induced 
cystitis rats (Table 2).  Intermediate (48 h) CYP-induced cystitis was chosen for analysis 
due to a robust increase in urinary bladder TGF-β ligand and receptor transcript and 
protein expression.   
Control (no inflammation) 
  Intravesical instillation of SB505124 (5 µM) significantly (p ≤ 0.05) decreased 
voiding frequency and increased bladder capacity (1.3-fold), void volume (1.4-fold) and 
intercontraction intervals (1.3-fold) relative to pre-drug baseline measurements (Table 2).  
Intravesical pressure (filling, threshold, peak) was not significantly affected following 
SB505124 (5 µM) instillation (Table 2).  Residual volume before or after SB505124 (5 
µM) instillation was minor (≤ 35 µL) and the effects of treatment persisted throughout 
the entirety of the experiment (1.5-2 h). 
Intermediate (48 h) CYP-induced cystitis 
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As previously demonstrated (3, 5, 29), intermediate (48 h) CYP-induced cystitis 
increased voiding frequency and intravesical pressure (filling, threshold, peak) and 
decreased bladder capacity, void volume and intercontraction intervals relative to control 
(no inflammation) rats (Table 2). Intravesical instillation of SB505124 (5 µM) 
significantly (p ≤ 0.001) decreased voiding frequency and increased bladder capacity 
(2.5-fold), void volume (2.6-fold) and intercontraction intervals (2.5-fold) relative to pre-
drug baseline measurements (Table 2, Figure 7).  SB505124 (5 µM) did not significantly 
affect intravesical pressure (filling, threshold, peak) in CYP-treated (48 h) rats (Table 2, 
Figure 7).  Residual volume before or after SB505124 (5 µM) instillation was minor (≤ 




   
Discussion 
The present study characterized the expression of urinary bladder TGF-β (1, 2 
and 3) and TβR (1, 2 and 3) following CYP-induced cystitis of varying durations and 
established a role for TGF-β signaling in micturition reflex function.  We confirmed the 
presence of a delayed TGF-β proinflammatory phenotype following acute urinary bladder 
inflammation and extended previous findings (45, 55) by demonstrating the functional 
expression and chronicity of urinary bladder TGF-β.  These results provide evidence for a 
novel molecular component of the urinary bladder inflammatory response that, when 
inhibited, reduces voiding frequency with urinary bladder dysfunction. 
The expression of TGF-β ligands in the urinary bladder proinflammatory 
cytokine milieu has been previously suggested to reflect the inflammatory state of the 
urinary bladder (55).  Zhang and Qiao (2012) have observed a step-wise TGF-β1 
transcript upregulation following acute (8 h) and intermediate (48 h) CYP-induced 
cystitis, while Tyagi et al. (2009) observed significant upregulation of TGF-β1 urinary 
bladder protein following acute (24 h) CYP-induced cystitis.  Similarly, the present study 
demonstrates an upregulation of TGF-β ligand and receptor expression following 
intermediate (48 h) or chronic CYP-induced cystitis, but not acute (4 h) CYP-induced 
cystitis.  The temporal regulation of TGF-β transcript and protein expression may aid in 
monitoring the urinary bladder inflammatory response and suggests an involvement in 
the resolution of urinary bladder inflammation to initiate tissue remodeling (45). 
In the remedial stages of inflammation, the urinary bladder undergoes alterations 
characterized by a deposition of extracellular matrix constituents and proliferation of 
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activated fibroblasts (13).  Although the precise contribution of TGF-β to pathological 
tissue remodeling is unknown, TGF-β is capable of promoting deposition of profibrotic 
extracellular matrix proteins and preventing matrix degradation by inhibiting expression 
of metalloproteinases and plasminogen-activators (8).  While neither the present nor past 
studies address the role of TGF-β in urinary bladder remodeling, our results suggest the 
profibrotic profile may be partly mediated by a delayed, long lasting TGF-β upregulation. 
Chronic urinary bladder inflammation is characterized by increased 
mononuclear cell infiltration, mucosal ulceration and the systemic release of 
proinflammatory cytokines and chemokines from distinct tissue compartments (40, 42).  
The present study not only demonstrated the temporal regulation of TGF-β but also the 
differential distribution of TGF-β ligands and its cognate receptors.  The regulation of 
TGF-β1 and TGF-β3 transcript expression in the urothelium appeared to contribute most 
to the global translational profiles observed in our conditions.  However, significant 
upregulation of TGF-β2 transcript in the urothelium was not sufficient to increase urinary 
bladder protein at any CYP-treatment duration.  These differences may reflect the 
elevated basal TGF-β2 transcript expression in the detrusor smooth muscle relative to the 
urothelium.  TβR (1, 2 and 3) transcript expression in the urothelium and detrusor smooth 
muscle was, in general, significantly increased following intermediate (48 h) or chronic 
CYP-induced cystitis.  These profiles were maintained in TβR-1 and TβR-2 antigen 
immunoreactivity in the urothelium, as well as TβR (1, 2 and 3) immunoreactivity in the 
detrusor smooth muscle.  The absence of urothelial TβR-3 immunoreactivity in control or 
CYP-treated animals may reflect transcript expression and regulation in the 
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suburothelium, transcript instability (27), decreased translation efficiency and/or 
increased receptor internalization (17). 
While the clinical presentation of IC/BPS is diverse, there remain 
histopathologic and immunologic features that may contribute to urinary bladder 
dysfunction. Cystoscopic and bladder biopsy examinations indicate IC/BPS patients may 
present with a constellation of signs and symptoms including: an exaggerated 
inflammatory response, intrafascicular fibrosis and detrusor mastocytosis (37, 39, 46).  
Our findings combined with the established role of TGF-β in cellular proliferation, 
differentiation and migration, suggests TGF-β ligand overexpression and subsequent 
intracellular signaling may contribute, in part, to the pathophysiology of our experimental 
cystitis model of IC/BPS.  To determine if aberrant TGF-β signaling contributes to 
urinary bladder dysfunction, we intravesically instilled a competitive ATP small 
molecule inhibitor, SB505124 (5 µM).  Due to the structural similarities between TGF-β 
activated ALKs, it is possible for SB505124 to have off target effects on activin A 
receptor, type IB (ACVR1B, ALK4).  While further studies are necessary to define the 
specific role(s) of ACVR1B and TβR-1 on urinary bladder dysfunction, SB505124 
demonstrates 2.5-fold less potency in vitro on ACVR1B SMAD phosphorylation 
suggesting it may have a greater influence on TGF-β signaling in vivo (12, 51). 
Instillation of SB505124 (5 µM) decreased voiding frequency in both control 
(no inflammation) and intermediate (48 h) CYP-induced cystitis rats, however, 
differences in fold change suggest TGF-β signaling has a more prominent role in 
micturition reflex function following urinary bladder inflammation.  These results not 
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only remain consistent with the transcriptional and translational overexpression profiles 
observed following intermediate (48 h) CYP-induced cystitis but also demonstrate a 
novel, albeit small, role for TGF-β in normal micturition reflex function.  
Cystometrogram recordings in control (no inflammation) rats following SB505124 (5 
µM) instillation revealed a role for basal urothelial TGF-β signaling in micturition reflex 
function due to the barrier properties provided by intact junction complexes and 
specialized apical proteins (4).  In addition, the absence of intravesical pressure changes 
suggests little to no effect on the urethral outlet and efferent limb of the micturition 
reflex.  Similar parameters (void frequency, infused and voided volume, intercontraction 
intervals) were altered following intermediate (48 h) CYP-induced cystitis and SB505124 
(5 µM) suggesting a role for aberrant TGF-β signaling in the afferent limb of the 
micturition reflex.  Specific tissues or cell types in the urinary bladder that contribute to 
the functional effects are less clear due to increases in urinary bladder permeability after 
CYP metabolism (16) and global TβR-1 overexpression.  Future studies can address 
suburothelial-specific overexpression of TβR-1 and/or determine the contributions of 
urothelial and detrusor smooth muscle TGF-β signaling to resolve our observed 
phenotypes. 
The combination of systemic proinflammatory cytokine release, mononuclear 
cell infiltration and the profibrotic resolution of inflammation may contribute to 
peripheral and central sensitization that may facilitate viscerosomatic hypersensitivity 
and bladder hyperreflexia observed in IC/BPS (42). Given the biological contributions 
TGF-β may have on urinary bladder dysfunction (45, 55) and its recently established role 
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in peripheral sensitization (56), the present study characterized TGF-β transcript and 
protein expression at the level of the urinary bladder and provided evidence for a 
functional role of TGF-β signaling in the afferent limb of the micturition reflex.  These 
studies demonstrate that targeting one component of the urinary bladder inflammatory 
response may be an effective strategy to reduce voiding frequency in an experimental 
cystitis model of IC/BPS. 
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Table 1: Primer sequences 
rTGF-β, Rat Transforming Growth Factor-Beta; 





   
Table 2: Cystometrogram recordings for control (no inflammation) or 
intermediate (48 h) CYP-induced cystitis rats with SB505124 (5 µM) or 0.01% 
DMSO instillation 
Intravesical instillation of SB505124 (5 µM) significantly decreased voiding frequency 
and increased bladder capacity (total infused 0.9% NaCl at the time micturition 
commenced), void volume and intercontraction intervals relative to pre-SB505124 
baseline measurements in both control (no inflammation) and intermediate (48 h) CYP-
induced cystitis rats. n=4-5 per condition; values are mean ± SEM; *p ≤ 0.05, ***p ≤ 





   
 
Figure 1: Time- and tissue-dependent regulation of TGF-β (1, 2 and 3) and TβR (1, 2 and 3) 
transcript expression following cyclophosphamide (CYP) treatment 
TGF-β (1, 2 and 3) and TβR (1, 2 and 3) transcript expression was not significantly regulated following 
acute (4 h) induced cystitis.  Intermediate (48 h) CYP-induced cystitis significantly increased TGF-β1 (A; 
urothelium/detrusor smooth muscle), TGF-β2 (B; urothelium), TGF-β3 (C; urothelium), TβR-1 (D; 
urothelium), TβR-2 (E; urothelium/detrusor smooth muscle) and TβR-3 (F; urothelium/detrusor smooth 
muscle) transcript expression relative to control.  Chronic CYP-induced cystitis significantly increased 
TGF-β2 (B; urothelium), TGF-β3 (C; urothelium), TβR-1 (D; urothelium/detrusor smooth muscle), TβR-2 
(E; urothelium) and TβR-3 (F; urothelium/detrusor smooth muscle) transcript expression relative to control.  
n=5-7 per condition; values are mean ± SEM; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 versus control.  
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Figure 2: Time-dependent regulation of TGF-β (1, 2 and 3) protein expression in whole rat urinary 
bladder following CYP treatment 
(A) TGF-β1 urinary bladder protein expression was significantly increased following intermediate (48 h) 
CYP-induced cystitis. (B) TGF-β2 urinary bladder protein expression did not significantly differ across any 
condition relative to control.  (C) TGF-β3 urinary bladder protein expression was significantly increased 
following intermediate (48 h) CYP-induced cystitis. n=8 per condition; values are mean ± SEM; *p ≤ 0.05, 
***p ≤ 0.001 versus control.  
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Figure 3: Time- and tissue-dependent regulation of TGF-β1 immunoreactivity (IR) following CYP 
treatment 
(A-D) Representative images of TGF-β1-IR in urothelium following control or CYP treatment paradigms.  
(E-H) Representative images of TGF-β1-IR in detrusor smooth muscle following control or CYP treatment 
paradigms.  (I) Semi-quantitative analyses in urothelium revealed a significant suprathreshold increase 
following intermediate (48 h) or chronic CYP-induced cystitis.  (J) Semi-quantitative analyses in detrusor 
smooth muscle revealed a significant suprathreshold increase following intermediate (48 h) or chronic 
CYP-induced cystitis.  L, lumen; U, urothelium; SU, suburothelium; sm, detrusor smooth muscle.   
Figure 3: Time- and tissue-dependent regulation of TGF-β1 immunoreactivity (IR) following CYP 
treatment.  
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Figure 4: Time- and tissue-dependent regulation of TβR-1 immunoreactivity (IR) following CYP 
treatment 
(A-D) Representative images of TβR-1-IR in urothelium following control or CYP treatment paradigms.  
(E-H) Representative images of TβR-1-IR in detrusor smooth muscle following control or CYP treatment 
paradigms.  (I) Semi-quantitative analyses in urothelium revealed a significant suprathreshold increase 
following intermediate (48 h) or chronic CYP-induced cystitis.  (J) Semi-quantitative analyses in detrusor 
smooth muscle revealed a robust suprathreshold trend following intermediate (48 h) or chronic CYP-
induced cystitis.  L, lumen; U, urothelium; SU, suburothelium; sm, detrusor smooth muscle.  Calibration 
bar represents 25 µm.  n=4 per condition; values are mean ± SEM; **p ≤ 0.01, ***p ≤ 0.001 versus control. 
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Figure 5: Time- and tissue-dependent regulation of TβR-2 immunoreactivity (IR) following CYP 
treatment 
(A-D) Representative images of TβR-2-IR in urothelium following control or CYP treatment paradigms.  
(E-H) Representative images of TβR-2-IR in detrusor smooth muscle following control or CYP treatment 
paradigms.  (I) Semi-quantitative analyses in urothelium revealed a significant suprathreshold increase 
following intermediate (48 h) or chronic CYP-induced cystitis.  (J) Semi-quantitative analyses in detrusor 
smooth muscle revealed a significant suprathreshold increase following intermediate (48 h) or chronic 
CYP-induced cystitis.  L, lumen; U, urothelium; SU, suburothelium; sm, detrusor smooth muscle.  
Calibration bar represents 25 µm.  n=4 per condition; values are mean ± SEM; **p ≤ 0.01, ***p ≤ 0.001 
versus control.  
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Figure 6: Time- and tissue-dependent regulation of TβR-3 immunoreactivity (IR) following CYP 
treatment 
(A-D) Representative images of TβR-3-IR in detrusor smooth muscle following control or CYP treatment 
paradigms.  (E) Semi-quantitative analyses in detrusor smooth muscle revealed a significant suprathreshold 
increase following intermediate (48 h) or chronic CYP-induced cystitis.  L, lumen; U, urothelium; SU, 
suburothelium; sm, detrusor smooth muscle.  Calibration bar represents 25 µm.  n=4 per condition; values 




   
 
Figure 7: Cystometrogram traces of TβR-1 inhibition following intermediate (48 h) CYP-induced 
cystitis 
(A) Representative pre-SB505124 baseline traces. (B) Representative post-SB505124 (5 µM) traces.  
Intravesical instillation of SB505124 (5 µM; B) significantly (p ≤ 0.001) decreased voiding frequency and 
increased bladder capacity (total infused 0.9% NaCl at the time micturition commenced; 2.5-fold), void 
volume (2.6-fold) and intercontraction intervals (2.5-fold) relative to pre-SB505124 baseline measurements 
(A).  Representative traces (A, B) were from the same rat.  
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CHAPTER 3: PURINERGIC SIGNALING UNDERLIES TRANSFORMING 
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Key Points 
 The sensory components of the urinary bladder are responsible for the 
transduction of bladder filling and are often impaired with neurological injury or 
disease. 
 Elevated extracellular ATP contributes, in part, to bladder afferent nerve 
hyperexcitability during neurogenic bladder inflammation or irritation.  
 TGF-β1 stimulates ATP release from the urothelium through vesicular exocytosis 
mechanisms with minimal contribution from pannexin-1 channels to increase 
bladder afferent nerve discharge. 
 Bladder afferent nerve hyperexcitability and urothelial ATP release with CYP-
induced cystitis is decreased with TGF-β inhibition. 
 These results establish a causal link between an inflammatory mediator, TGF-β, 
and intrinsic signaling mechanisms of the urothelium that may contribute to the 
altered sensory processing of bladder filling. 
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Abstract 
The afferent limb of the micturition reflex is often compromised following bladder 
injury, disease and inflammatory conditions. We have previously demonstrated that 
transforming growth factor-beta (TGF-β) signaling contributes to increased voiding 
frequency and decreased bladder capacity with cystitis. Despite the functional presence of 
TGF-β in bladder inflammation, the precise mechanisms of TGF-β mediating bladder 
dysfunction are not yet known. Thus, the present studies investigated the sensory 
components of the urinary bladder that may underlie the pathophysiology of aberrant 
TGF-β activation. We utilized bladder-pelvic nerve preparations to characterize bladder 
afferent nerve discharge and the mechanisms of urothelial ATP release with distention. 
Our findings indicate that bladder afferent nerve discharge is sensitive to elevated 
extracellular ATP during pathological conditions of neurogenic bladder inflammation or 
irritation. We determined that TGF-β1 increased bladder afferent nerve excitability by 
stimulating ATP release from the urothelium via vesicular exocytosis mechanisms with 
minimal contribution from pannexin-1 channels. Furthermore, blocking aberrant TGF-β 
signaling in cyclophosphamide-induced cystitis with TβR-1 inhibition decreased afferent 
nerve hyperexcitability with a concomitant decrease in urothelial ATP release. Taken 
together, these results establish a role for purinergic signaling mechanisms in TGF-β 
mediated bladder afferent nerve activation that may ultimately facilitate increased 
voiding frequency. The synergy between intrinsic urinary bladder signaling mechanisms 
and an inflammatory mediator provides novel insight into bladder dysfunction and 
supports new avenues for therapeutic intervention. 
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Abbreviations. BFA, Brefeldin A; CYP, cyclophosphamide; Det, detrusor smooth 
muscle; ICC, interstitial cells of Cajal; P2X/P2Y, purinergic receptor; Panx1, pannexin 1; 
PPADS, pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid; PSS, physiological saline 
solution; TGF-β, transforming growth factor-beta; TβR, transforming growth factor-β 
receptor. 
Keywords: urinary bladder, TGF-β, ATP, inflammation 
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Introduction 
The transitional epithelial cells that line the bladder lumen are now recognized 
to act as a passive barrier to urinary metabolites (Min et al., 2003) and contribute to the 
sensory transduction of bladder filling (Birder, 2005). These cells, termed the urothelium, 
respond to mechanical (Olsen et al., 2011) or chemical (Everaerts et al., 2010) stimuli by 
releasing urinary proteins (Deng et al., 2001) or neuroactive signaling molecules 
(Ferguson et al., 1997; Birder et al., 2002; Hanna-Mitchell et al., 2007; Nile & Gillespie, 
2012) from their apical and basolateral surfaces (Lewis & Lewis, 2006). The release of 
these mediators presumably permits the urothelium to communicate with nerve endings 
(Morrison, 1999; Andersson, 2002) and other cell types such as interstitial cells of Cajal 
(ICC) (Sui et al., 2008; Drumm et al., 2014) or smooth muscle cells (Hashitani et al., 
2004) that are proximal to the mucosa. Given the role that the urothelium has in bladder 
sensation, any disruption to these signaling mechanisms, such as what may occur with 
inflammation (de Groat & Yoshimura, 2009), may contribute to the development of 
lower urinary tract symptoms (Gonzalez et al., 2014b). 
Purinergic signaling has garnered much of the focus in bladder sensory 
processing ever since the urothelium was discovered to release ATP (Ferguson et al., 
1997). The mechanisms of ATP release from the urothelium have since been 
demonstrated to include vesicular exocytosis (Wang et al., 2005; Sui et al., 2014; 
McLatchie & Fry, 2015), ion channels (Wang et al., 2005; Sui et al., 2014; Beckel et al., 
2015; McLatchie & Fry, 2015) and transporters (Wang et al., 2005). Extracellular ATP 
and other associated nucleotides may then bind to purinergic receptors located on various 
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cell types (e.g. urothelial (Tempest et al., 2004; Chopra et al., 2008), smooth muscle 
(Heppner et al., 2005) and ICC (Wu et al., 2004)) or nerve terminals (Namasivayam et 
al., 1999; Andersson, 2002) to activate autocrine or paracrine pathways and facilitate 
bladder sensory signaling (Birder & Andersson, 2013). Purinergic signaling in these cell 
types has been demonstrated to increase sensory neuron excitability (Chen et al., 1995) 
and to modulate smooth muscle tone (Sui et al., 2014). Furthermore, aberrant purinergic 
signaling in the urothelium has been suggested to contribute to bladder dysfunction in 
injury or disease since ATP release is increased in many functional disorders of the 
urinary bladder (Sun et al., 2001; Ruggieri, 2006; Sun & Chai, 2006; Silva-Ramos et al., 
2013). 
In addition to alterations in the intrinsic properties of the urothelium, functional 
disorders of the bladder that activate an inflammatory response may also involve an 
upregulation of proinflammatory mediators (Gonzalez et al., 2014a). Previous studies 
from our laboratory have established the roles of cytokines (Malley & Vizzard, 2002) and 
chemokines (Arms et al., 2010; Arms et al., 2013) in the maintenance and development 
of lower urinary tract symptoms. In particular, we have demonstrated that transforming 
growth factor-beta (TGF-β) overexpression contributes to the afferent limb of the 
micturition reflex with cyclophosphamide (CYP)-induced cystitis (Gonzalez et al., 2013). 
In addition to its role(s) in cystitis, increased urinary TGF-β has also been observed in 
diabetic nephropathy (Chen et al., 2003) and other nephropathic conditions (Goumenos et 
al., 2002; De Muro et al., 2004) with bladder dysfunction (Golbidi & Laher, 2010). 
Despite its functional presence in the bladder inflammatory milieu, the precise 
106 
   
mechanisms of TGF-β mediating voiding dysfunction are not yet known. Therefore, we 
hypothesized that TGF-β signaling contributes to afferent nerve excitability through 
purinergic mechanisms that may ultimately facilitate increased voiding frequency. A 
comprehensive understanding of the downstream signaling effectors that interact in the 
afferent limb of the micturition reflex with bladder dysfunction will allow for novel 
therapeutic approaches to improve the quality of life of these patients. 
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Materials and Methods 
Ethical Approval 
Experimental procedures were approved by the University of Vermont 
Institutional Animal Care and Use Committee (protocol 08-055) and experiments were 
conducted in accordance with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals (8th edn). 
Animals 
Male C57Bl/6 mice (3-6 months old) purchased from Jackson Laboratories (Bar 
Harbor, ME) were housed with littermates and maintained in standard laboratory 
conditions with food and water available ad libitum.  
Induction of CYP-induced cystitis 
Male C57Bl/6J mice (n=4) received a 150 mg/kg I.P. injection of CYP (Sigma-
Aldrich, St. Louis, MO). Mice were harvested 48 h following CYP treatment for bladder-
pelvic nerve electrophysiology or ATP release experiments. 
Bladder-pelvic nerve electrophysiology 
The bladder-pelvic nerve model was developed and described in detail by 
Namasivayam et al. (1998). Briefly, male C57Bl/6J mice (n=3-4) were euthanized by an 
injection of pentobarbital sodium (I.P.) followed by decapitation. The abdominal cavity 
was opened by a midline incision and the urinary bladder and surrounding tissues 
(urethra, ureters, major pelvic ganglia, postganglionic nerves and pelvic nerves) were 
excised and transferred to ice-cold dissection solution. The ureters were isolated, 
dissected and ligated with nylon suture adjacent to the bladder wall. The pelvic nerves 
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were isolated and the ends were cleaned of connective tissue to facilitate recording. The 
urinary bladder, urethra, ureters and pelvic nerves were then transferred to a recording 
chamber on a vibraplane platform and superfused with biological atmosphere gas (20% 
O2, 5% CO2, 75% N2) physiological saline solution (PSS) circulating at 37 °C. One arm 
of a triple lumen cannula was inserted through the urethra into the bladder and ligated. 
The remaining arms were attached to a remote-controlled syringe pump and pressure 
transducer to monitor intravesical pressure or used to empty the bladder. One of the 
pelvic nerves was attached to a suction electrode to record distention-evoked multifiber 
afferent nerve activity. With this recording arrangement, we did not identify the relative 
contribution(s) of myelinated Aδ fibers and the normally quiescent umyelinated C fibers. 
Vehicle or drugs were administered at a rate of 30 µl/min intravesically up to 25 mmHg 
for the filling phase and then manually emptied. There was a 10 min rest period between 
the emptying phase and the start of the next filling phase. For the co-administration 
studies, bladders were first pretreated with the various inhibitors followed by the 
inhibitors plus TGF-β1. Administration of drugs began once bladder afferent nerve 
activity to the vehicle plateaued for two consecutive filling phases (usually after 5-6 
filling cycles). Bladder afferent nerve activity was collected and amplified with a 
Neurolog head stage (NL104, Digitimer), filtered (band pass 200-4000 Hz) using a 
Digitimer NL125/Nl126 filter and digitized with a Power 1401 analog to digital interface 
(Cambridge Electronic Design, Cambridge, UK). The acquisition rates for nerve activity 
and bladder pressure were 25,000 Hz and 100 Hz, respectively. Data were analyzed 
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offline via Spike 2 software (version 5.11, Cambridge Electronic Design, Cambridge, 
UK). 
Analysis:  Action potentials were determined by using twice the root mean 
square amplitude of the recording signal for detection threshold. Action potential events 
were quantified in 5 mmHg increments to determine activity throughout multiple 
pressures in the filling phase. The mean frequency (imp/sec) graphed for each condition 
(vehicle or drug) per animal was the average of two consecutive filling phases. A two-
way repeated measures ANOVA followed by Sidak’s multiple comparisons test was then 
performed to compare these frequency group means. Fold change group means were 
compared with Student’s unpaired t test. 
ATP release 
Male C57Bl/6J mice (n=4-8) were anesthetized with 2% isoflurane and 
euthanized by decapitation. The abdominal cavity was opened by a midline incision and 
the urinary bladder, urethra and ureters were excised and transferred to ice-cold 
dissection solution. The ureters were isolated, dissected and ligated with nylon suture 
adjacent to the bladder wall. The urinary bladder, urethra and ureters were then 
transferred to a recording chamber with oxygenated (95% O2-5% CO2) PSS circulating 
at 37 °C and cannulated through the urethra with a 22 gauge blunt needle. The cannula 
was attached to a remote-controlled syringe pump and a pressure transducer to monitor 
intravesical pressure. Vehicle or drugs were administered at a rate of 30 µl/min 
intravesically up to 25 mmHg for the filling phase and then manually emptied via a three-
way stop cock. There was a 10 min rest between the emptying phase and the start of the 
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next filling phase. After 1-1.5 h of vehicle or drug administration, the instillate was 
collected from two separate but consecutive emptying cycles and immediately flash 
frozen until ATP analysis. Upon collection, CYP instillate samples also received 
adenylyl-imidodiphosphate (AMP-PNP, 200 µM) to limit ATP hydrolysis that may be 
present from a compromised barrier. ATP quantification was determined with the ATP 
bioluminescent assay kit (Sigma-Aldrich, St. Louis, MO) following their procedural 
instructions with the exception of halving the recommended concentration of reagents 
and samples. ATP measurements were taken with the BioTek H4 Plate Reader 
(Winooski, VT) within the UVM Advanced Genome Technologies Core.  
Analysis:  The bioluminescence emitted by the sample was plotted against the 
calibration curve to determine the final concentration (pmol/ml) of ATP. Calibration 
curves were not affected by the drugs used in the current study (data not shown). 
Statistical analysis was performed on the ATP concentration (pmol/ml) of the instillate 
before or after drug administration as Student’s paired t test for all group means. 
Materials 
The dissection solution consisted of (in mM) 55 NaCl, 6 KCl, 80 MSG, 10 
HEPES, 2 MgCl2, 10 glucose, and adjusted to pH 7.3. The PSS consisted of (in mM) 119 
NaCl, 4.7 KCl, 24 NaHCO3, 1.2 KH2PO4, 1.2 MgCl2, 2 CaCl2, 7 glucose, and adjusted 
to pH 7.4. Recombinant mouse transforming growth factor-beta 1 (TGF-β1, R&D 
Systems) was reconstituted to 50 µg/ml in 4 mM HCl and 0.1% BSA and stored at -20 
°C. Bladder tissues respond to a range of TGF-β1 concentrations (Hiti et al., 1990; Duan 
et al., 2015) and 10 ng/ml was selected for as the working concentration as it does not 
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induce EMT related genes in the urothelium (Islam et al., 2014). SB505124 (R&D 
Systems) was reconstituted to 100 mM in DMSO (99.5%) and stored at -20 °C. 
SB505124 is a potent inhibitor of TGF-β type I receptor kinase activity with an IC50 of 
47 ± 5 nM (DaCosta Byfield et al., 2004). Before its use, stock solutions were diluted to a 
working concentration (5 µM) with PSS. Concentrations up to 5 μM maintain inhibition 
specificity of downstream targets of TβR-1 and other closely related receptors and have 
been demonstrated to decrease voiding frequency with cystitis (DaCosta Byfield et al., 
2004; Gonzalez et al., 2013). Brefeldin A (BFA, R&D Systems) was reconstituted to 50 
mM in DMSO (99.5%) and stored at -20 °C. Stock solutions were diluted to a working 
concentration (10 µM) with PSS to remain consistent with previous literature 
demonstrating decreased ATP release from the urothelium (Sui et al., 2014; McLatchie & 
Fry, 2015). 10Panx (R&D Systems) was reconstituted to 1 mg/ml in PSS and stored at -
20 °C. The IC50 of 10Panx for the inhibition of panx1 currents in overexpressed panx1 
HEK cells is 52 ± 12 μM (Pelegrin & Surprenant, 2006). We utilized 10Panx at a 
working concentration of 50 μM because intravesical 10Panx near the IC50 concentration 
was functional in the urinary bladder to decrease voiding frequency (Timoteo et al., 
2014). Pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid tetrasodium salt (PPADS, 
R&D Systems) was reconstituted to 100 mM in distilled water and stored protected from 
light at -20 °C to prevent photodecomposition. A working concentration of 300 μM was 
selected for PPADS because Vlaskovska et al. (2001) reported decreased distention-
evoked afferent nerve discharge in control tissues that was not observed at lower 
concentrations (Yu & de Groat, 2008). 
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Statistics 
All values represent means ± SEM. Outliers were identified using the extreme 
studentized deviate test on GraphPad Prism (v. 6.07, La Jolla, CA) and excluded from 
further analysis. Data were then compared with two-way repeated measures ANOVA and 
two-tailed Student’s unpaired or paired t test where appropriate. When F-test statistic 
exceeded the critical value at α = 0.05, the Sidak’s multiple comparisons test was used to 
compare group means. 
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Results 
TGF-β1 increased bladder afferent nerve discharge and ATP release from the 
urothelium. 
The continuous intravesical instillation of recombinant TGF-β1 (10 ng/ml) had a 
significant (p = 0.0447) treatment effect on mean bladder afferent nerve frequency 
(imp/sec) (Figure 1A, Figure 1B). Nerve firing increased (50.5 ± 9.9 to 71.6 ± 13.3 
imp/sec, n=4) by 41.8% from 0-25 mmHg with TGF-β1 instillation. More specifically, 
nerve discharge significantly increased from 5-10 (p = 0.0337), 10-15 (p = 0.0003), 15-20 
(p ≤ 0.0001) and 20-25 (p ≤ 0.0001) mmHg (Figure 1B). Distention-evoked ATP release 
from the urothelium at 25 mmHg was also significantly (p = 0.0066) increased with the 
intravesical instillation of TGF-β1 (Figure 1C). 
The concurrent intravesical instillation of TGF-β1 and SB505124 (5 µM), a 
TGF-β type I receptor inhibitor, attenuated (p = 0.4396) afferent nerve hyperexcitability 
(76.8 ± 17.7 to 61.8 ± 12.9 imp/sec, n=4) from 0-25 mmHg (Figure 2C, Figure 2D). 
SB505124 co-administration also attenuated (p = 0.3245) TGF-β1 mediated distention-
evoked urothelial ATP release at 25 mmHg (Figure 2E). The intravesical administration 
of SB505124 (5 µM) alone did not have a significant (p = 0.6506) treatment effect on 
mean nerve firing (76.8 ± 17.7 to 63.9 ± 13.6 imp/sec, n=4) from 0-25 mmHg (Figure 
2A, Figure 2B). Furthermore, SB505124 did not have a significant (p = 0.0782) effect on 
distention-evoked urothelial ATP release at 25 mmHg (4.8 ± 1.7 to 7.2 ± 2.5 pmol/ml, 
n=4). 
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TGF-β1 stimulated ATP release from the urothelium through vesicular exocytosis 
mechanisms to mediate bladder afferent nerve hyperexcitability. 
Vesicular ATP release. The continuous intravesical instillation of BFA (10 µM) 
did not have a significant (p = 0.8960) treatment effect on mean bladder afferent nerve 
firing (68.7 ± 12.6 to 58.7 ± 15.1 imp/sec, n=3) from 0-25 mmHg (Figure 3A, Figure 
3B). Similarly, the intravesical co-administration of recombinant TGF-β1 (10 ng/ml) and 
BFA (10 µM) did not have a significant (p = 0.5646) treatment effect on mean nerve 
firing (68.7 ± 12.6 to 63.4 ± 21.4 imp/sec, n=3) from 0-25 mmHg (Figure 3C, Figure 
3D). The intravesical co-administration of BFA also attenuated (p = 0.2155) TGF-β1 
mediated distention-evoked urothelial ATP release at 25 mmHg (Figure 3E). 
Pannexin-1 channel ATP release. The continuous intravesical instillation of 
10Panx (50 µM) did not have a significant (p = 0.1340) treatment effect on mean bladder 
afferent nerve firing (41.9 ± 1.8 to 42.8 ± 3.9 imp/sec, n=4) from 0-25 mmHg (Figure 4A, 
Figure 4B). The intravesical co-administration of recombinant TGF-β1 (10 ng/ml) and 
10Panx (50 µM), however, had a significant (p = 0.0213) treatment effect on mean nerve 
frequency with nerve firing increased (41.9 ± 1.8 to 50.1 ± 3.4 imp/sec, n=4) by 19.4% 
from 0-25 mmHg (Figure 4C, Figure 4D). More specifically, nerve discharge 
significantly increased from 10-15 (p = 0.0014), 15-20 (p ≤ 0.0001) and 20-25 (p = 
0.0008) mmHg (Figure 4D). Relative to TGF-β1 alone (1.67 fold, Figure 1B), TGF-β1 
and 10Panx co-administration (1.18 fold, Figure 4D) significantly (p = 0.0397) decreased 
the magnitude of change only from 20-25 mmHg. Distention-evoked urothelial ATP 
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release at 25 mmHg was also significantly (p = 0.0465) increased with the intravesical 
co-administration of TGF-β1 and 10Panx (Figure 4E). 
Purinoceptor signaling. The continuous intravesical instillation of PPADS (300 
µM) did not have a significant (p = 0.2339) treatment effect on mean bladder afferent 
nerve firing (75.9 ± 25.1 to 64.0 ± 16.9 imp/sec, n=4) from 0-25 mmHg (Figure 5A, 
Figure 5B). The intravesical co-administration of recombinant TGF-β1 (10 ng/ml) and 
PPADS (300 µM) attenuated (p = 0.2941) afferent nerve hyperexcitability (75.9 ± 25.1 to 
59.2 ± 11.9 imp/sec, n=4) from 0-25 mmHg (Figure 5C, Figure 5D). The intravesical co-
administration of TGF-β1 and PPADS, however, significantly (p = 0.0403) increased 
distention-evoked urothelial ATP release at 25 mmHg (Figure 5E). 
Bladder afferent nerve hyperexcitability and urothelial ATP release with CYP-induced 
cystitis is decreased with TGF-β inhibition. 
CYP-induced cystitis had a significant (p ≤ 0.0001) treatment effect on mean 
bladder afferent nerve frequency (imp/sec) and nerve firing increased (62.2 ± 7.2 to 179.8 
± 20.9 imp/sec, n=4-19) by 188.9% from 0-25 mmHg relative to control (Figure 6A, 
Figure 6B). Nerve discharge significantly increased from 5-10 (p ≤ 0.0001), 10-15 (p ≤ 
0.0001), 15-20 (p ≤ 0.0001) and 20-25 (p ≤ 0.0001) mmHg (Figure 6B). The continuous 
intravesical instillation of SB505124 (5 µM) significantly (p = 0.0028) decreased mean 
nerve frequency with CYP-induced cystitis (Figure 6C, Figure 6D). Mean nerve firing 
decreased (179.8 ± 20.9 to 103.6 ± 6.0 imp/sec, n=4) by 40.6% from 0-25 mmHg with a 
significant decrease in discharge from 5-10 (p = 0.0041), 10-15 (p = 0.006) and 15-20 (p 
= 0.0197) mmHg following SB505124 instillation (Figure 6D). TβR-1 inhibition with 
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SB505124 also significantly (p = 0.0190) decreased distention-evoked urothelial ATP 
release at 25 mmHg following CYP-induced cystitis (Figure 6E). The vehicle wash out of 
SB505124 increased nerve firing (103.6 ± 6.0 to 172.8 ± 21.9 imp/sec, n=4) and 
urothelial ATP release (6.3 ± 2.9 to 17 ± 3.7 pmol/ml, n=4) back to baseline. 
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Discussion 
The present study revealed that purinergic signaling mechanisms underlie TGF-
β mediated bladder afferent nerve excitability in both control and CYP-treated tissues. 
We determined that TGF-β1 contributes to bladder afferent nerve hyperexcitability 
through increased ATP release from the urothelium by vesicular exocytosis mechanisms. 
We also demonstrated that blocking aberrant TGF-β signaling in cystitis with TβR-1 
inhibition decreased bladder afferent nerve discharge and urothelial ATP release. These 
studies delineate the sensory components of the urinary bladder that may underlie the 
interface between the upregulation of inflammatory mediators and bladder dysfunction. 
ATP release.  The urothelium participates in the sensory processing of bladder 
filling by releasing neuroactive factors, such as ATP (Wang et al., 2005; Birder & 
Andersson, 2013). The altered release of ATP in many functional disorders of the urinary 
bladder (Sun et al., 2001; Sun & Chai, 2006; Silva-Ramos et al., 2013) suggest purinergic 
signaling may contribute to the pathophysiology of bladder dysfunction (Ruggieri, 2006). 
We determined that a previously identified inflammatory mediator of cystitis, TGF-β1 
(Gonzalez et al., 2013), was able to stimulate an increase in distention-evoked release of 
ATP from the urothelium (Figure 1D). The release of ATP was specific to ligand/receptor 
activation because the co-administration of TGF-β1 with a TβR-1 inhibitor, SB505124 
(DaCosta Byfield et al., 2004), attenuated an elevation in extracellular ATP (Figure 2F). 
Not surprisingly, TGF-β1 continued to stimulate distention-evoked ATP release from the 
urothelium when P2 receptors were inhibited downstream of the release pathways with 
the co-administration of PPADS (Figure 5F). Aberrant TGF-β activation that was 
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previously observed with CYP-induced cystitis (Gonzalez et al., 2013) also contributed to 
altered ATP release. In our studies with cystitis, the inhibition of aberrant TGF-β 
signaling significantly reduced urothelial ATP release that recovered immediately with 
vehicle washout (Figure 6F). These results suggest that TGF-β signaling may directly 
contribute to the altered sensory processing of bladder filling by increasing ATP release 
from the urothelium. 
Urothelial cells release ATP through various mechanisms that include vesicular 
exocytosis (Wang et al., 2005; Sui et al., 2014; McLatchie & Fry, 2015), 
connexin/pannexin channels (Wang et al., 2005; Sui et al., 2014; Beckel et al., 2015; 
McLatchie & Fry, 2015) and nucleoside transporters (Wang et al., 2005). Although each 
mechanism may play a part in release, our studies focused on the pharmacological 
manipulation of vesicular exocytosis and pannexin-1 channels due to the disputed role of 
transporters in uroepithelial cells (Knight et al., 2002) and because TGF-β1 
downregulates connexin hemichannels in the bladder (Neuhaus et al., 2009) suggesting 
an alternative mechanism for increased ATP release. We intravesically instilled the 
general secretory inhibitor, BFA, for vesicular release inhibition. BFA has previously 
been shown to decrease mechanical- and stretch-evoked ATP release from the urothelium 
(Wang et al., 2005; Sui et al., 2014; McLatchie & Fry, 2015). We also intravesically 
instilled the inhibitory peptide, 10Panx, to block pannexin-1 channels. These channels 
have recently been implicated in distention-evoked ATP release from the urothelium with 
pharmacological or genetic manipulation (Negoro et al., 2014; Timoteo et al., 2014; 
Beckel et al., 2015). 
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Our studies with BFA or 10Panx co-administration with TGF-β1 demonstrated 
that the majority of urothelial ATP release stimulated by TGF-β1 occurred through 
vesicular exocytosis (Figure 3F, Figure 4F). While these results suggest a vesicular 
secretory mechanism, the effects of BFA may also generalize to inhibit the transport of 
cell surface proteins, like hemichannels, to attenuate release (Wang et al., 2005). Further 
studies are needed to separate the effects of vesicle release and hemichannel inhibition, 
however, given that TGF-β1 downregulates connexin hemichannels and pannexin-1 
channels had a minimal role in TGF-β1 stimulated ATP release, it is likely that the effects 
we observed are due to vesicular secretory release. Future studies in our lab will aim to 
resolve the intracellular signaling cascade that may promote ATP release through these 
mechanisms. 
Bladder afferent nerve excitability.  Purinergic signaling is recognized to 
directly influence the afferent limb of the micturition reflex and bladder function. The 
intravesical instillation of ATP enhanced spinal bladder neuron excitability (Munoz et al., 
2011) and increased bladder activity (Pandita & Andersson, 2002). Non-voiding bladder 
contractions and voiding frequency, on the other hand, were decreased when ATP release 
was attenuated with the inhibition of vesicular (Smith et al., 2005) or pannexin-1 channel 
(Timoteo et al., 2014; Beckel et al., 2015) release mechanisms, respectively. Our studies 
determined that the decrease in distention-evoked ATP release from the urothelium 
through vesicular exocytosis or pannexin-1 channels did not significantly contribute to 
mechanosensitive afferent nerve discharge. This suggests that the decrease in bladder 
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function previously observed occurred through an as yet unknown mechanism that is 
independent of afferent nerve excitability. 
Extracellular ATP may contribute to bladder sensory processing through the 
activation of purinergic receptors on various cell types within the bladder wall including 
afferent nerve terminals. The activation of P2 receptors with intravesical alpha,beta-
methylene ATP or ATP increased bladder afferent nerve discharge (Yu & de Groat, 
2008) that was mediated mainly through capsaicin-insensitive C fibers (Aizawa et al., 
2011). Following intravesical P2 receptor inhibition, bladder activity decreased (Beckel 
et al., 2015) and afferent nerve discharge decreased (Namasivayam et al., 1999; 
Vlaskovska et al., 2001) or remained the same (Yu & de Groat, 2008). Our current study 
determined that intravesical PPADS decreased nerve frequency by 15.7% but did not 
have a significant effect on afferent nerve discharge. Taken together, these conflicting 
studies indicate that purinergic receptors may only be activated on C fibers during 
pathological conditions of elevated extracellular ATP to contribute to the sensation of 
bladder filling. 
The aforementioned contributions of purinergic signaling to bladder sensory 
transduction and function suggests that an insult, like inflammation, that alters ATP 
release may also affect nerve excitability. Given the functional overexpression of TGF-β 
in CYP-induced cystitis (Tyagi et al., 2009; Zhang & Qiao, 2012; Gonzalez et al., 2013) 
and its ability to stimulate ATP release in our current studies, we sought to determine if 
TGF-β1 also contributes to bladder afferent nerve hyperexcitability. The intravesical 
instillation of TGF-β1 increased nerve excitability by 41.8% and its significant effects on 
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nerve discharge were observed nearly throughout the entirety of the filling phase (Figure 
1D). Nerve hyperexcitability was dependent on receptor activation and subsequent 
release of ATP because the intravesical co-administration of TGF-β1 and a TβR-1 
inhibitor, SB505124, attenuated ATP release and bladder afferent nerve discharge (Figure 
2F). 
In addition to the necessity of TGF-β receptor activation, we also demonstrated 
that TGF-β1 stimulates ATP release through vesicular exocytosis to increase afferent 
nerve firing. Decreasing the release of ATP from the urothelium with BFA co-
administration attenuated TGF-β1 mediated afferent nerve hyperexcitability (Figure 3F). 
The co-administration of TGF-β1 and 10Panx, however, significantly increased 
distention-evoked ATP release and afferent nerve discharge suggesting minimal 
contribution from pannexin-1 channels in this response (Figure 4F). The elevated 
extracellular ATP stimulated by TGF-β1 is likely activating nerve terminals within the 
bladder wall to increase excitability. We demonstrated that the intravesical co-
administration of PPADS attenuated TGF-β1 mediated bladder afferent nerve 
hyperexcitability suggesting a role for these purinergic receptors in suburothelial afferent 
nerve firing (Figure 5F). Intravesical PPADS may also be working at the level of the 
urothelium to inhibit further basolateral release of ATP or other mediators that enhance 
excitability (Figure 5F) (Sun & Chai, 2006). Future studies are still needed to determine 
the basolateral release of ATP in this model because the concentrations of ATP that we 
quantified in the lumen likely underrepresents basolateral release onto sensory fibers due 
to volume differences in the interstitium, tissue-associated 
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ectonucleotidases/exonucleotidases (Wang et al., 2005) and cell-type specific ATP 
release (Cheng et al., 2011; McLatchie & Fry, 2015). Currently, the direct activation of 
purinergic receptors within the wall of an intact urinary bladder remains difficult to 
investigate without disrupting normal bladder physiology. 
TGF-β is increased in the urine (Tyagi et al., 2009), urothelium (Tyagi et al., 
2009; Gonzalez et al., 2013) and detrusor smooth muscle (Zhang & Qiao, 2012; Gonzalez 
et al., 2013) following CYP-induced cystitis. CYP-induced cystitis is characterized by 
voiding dysfunction and TGF-β is considered to contribute, in part, to the development of 
these lower urinary tract symptoms because TβR-1 inhibition decreased voiding 
frequency and increased bladder capacity (Gonzalez et al., 2013). We confirmed that 
bladder afferent nerve hyperexcitability is increased in CYP-induced cystitis (Yu & de 
Groat, 2008) and demonstrated a functional role for aberrant TGF-β signaling in this 
response (Figure 6F). Our current studies determined that TβR-1 inhibition may improve 
voiding dysfunction by decreasing ATP release from the urothelium and decreasing nerve 
firing by 40.6%. These effects were specific to aberrant TGF-β activation because vehicle 
washout increased ATP release and recovered nerve hyperexcitability to baseline. The 
decreased release of ATP with TβR-1 inhibition may normalize purinergic signaling and 
work comparably to intravesical P2X inhibition that has been previously reported to 
decrease afferent nerve excitability in CYP-induced cystitis (Yu & de Groat, 2008). It 
should also be noted that while TβR-1 inhibition significantly decreased distention-
evoked ATP release and afferent nerve excitability, nerve frequency did not reach control 
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activity suggesting that other neuroactive mediators may be influencing 
mechanosensitive nerve discharge with cystitis. 
Conclusion.  In summary, our studies highlight the role of purinergic signaling 
in TGF-β mediated bladder afferent nerve hyperexcitability. The apparent synergy 
between a component of the bladder inflammatory milieu and intrinsic signaling 
mechanisms discussed here will contribute to the understanding of the pathophysiology 
of bladder injury or disease. The distinct interactions of multiple signal transducers 
underscore the challenges for single target therapies and support the development of 
combinatory therapeutics for bladder dysfunction. 
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Figure 1: TGF-β1 increased distention-evoked bladder afferent nerve discharge and ATP release 
 (A) Representative traces of vehicle (gray) and recombinant TGF-β1 (10 ng/ml, black) instillation from the 
same preparation. (B) TGF-β1 significantly increased mean bladder afferent nerve frequency (imp/sec) by 
41.8% relative to control with significant nerve discharge increase from 5-10, 10-15, 15-20 and 20-25 
mmHg. (C) TGF-β1 significantly increased distention-evoked ATP release at 25 mmHg. (D) Proposed 
mechanisms of purinergic signaling with TβR activation. n=4-8; values are mean ± SEM; *p ≤ 0.05, ***p ≤ 
0.001, ****p ≤ 0.0001 by two-way repeated measures ANOVA followed by Sidak’s multiple comparisons 
test. #p ≤ 0.01 by Student’s paired t test.  
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Figure 2: Distention-evoked bladder afferent nerve discharge and ATP release are unchanged with 
the co-administration of TGF-β1 and SB505124 
(A) Representative traces of vehicle (gray) and SB505124 (5 μM, black) instillation from the same 
preparation. (B) SB505124 did not have a significant treatment effect on mean bladder afferent nerve 
frequency (imp/sec) relative to control. (C) Representative traces of vehicle (gray) and recombinant TGF-
β1 (10 ng/ml, black) and SB505124 (5 μM, black) co-instillation from the same preparation. Concurrent 
instillation of TGF-β1 and SB505124 attenuated distention-evoked bladder afferent nerve hyperexcitability 
(D) and ATP release (E) mediated by TGF-β1. (F) Proposed mechanisms of purinergic signaling with TβR 
inhibition. n=4-7; values are mean ± SEM. 
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Figure 3: Distention-evoked bladder afferent nerve discharge and ATP release are unchanged with 
the co-administration of TGF-β1 and BFA 
(A) Representative traces of vehicle (gray) and BFA (10 μM, black) instillation from the same preparation. 
(B) BFA did not have a significant treatment effect on mean bladder afferent nerve frequency (imp/sec) 
relative to control. (C) Representative traces of vehicle (gray) and recombinant TGF-β1 (10 ng/ml, black) 
and BFA (10 μM, black) co-instillation from the same preparation. Concurrent instillation of TGF-β1 and 
BFA attenuated distention-evoked bladder afferent nerve hyperexcitability (D) and ATP release (E) 
mediated by TGF-β1. (F) Proposed mechanisms of purinergic signaling with TβR activation and BFA. n=3-
8; values are mean ± SEM. 
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Figure 4: TGF-β1 and 10Panx co-administration increased distention-evoked bladder afferent nerve 
discharge and ATP release 
(A) Representative traces of vehicle (gray) and 10Panx (50 μM, black) instillation from the same 
preparation. (B) 10Panx did not have a significant treatment effect on mean bladder afferent nerve 
frequency (imp/sec) relative to control. (C) Representative traces of vehicle (gray) and recombinant TGF-
β1 (10 ng/ml, black) and 10Panx (50 μM, black) co-instillation from the same preparation. (D) Concurrent 
instillation of TGF-β1 and 10Panx significantly increased mean bladder afferent nerve frequency (imp/sec) 
by 19.4% relative to control with significant nerve discharge increase from 10-15, 15-20 and 20-25 mmHg. 
(E) TGF-β1 significantly increased distention-evoked ATP release at 25 mmHg when co-administered with 
10Panx. (F) Proposed mechanisms of purinergic signaling with TβR activation and 10Panx. n=4-7; values 
are mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, **** p ≤ 0.0001 by two-way repeated measures 
ANOVA followed by Sidak’s multiple comparisons test. #p ≤ 0.05 by Student’s paired t test. 
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Figure 5: Distention-evoked bladder afferent nerve discharge is unchanged but ATP release is 
increased with the co-administration of TGF-β1 and PPADS 
(A) Representative traces of vehicle (gray) and PPADS (300 μM, black) instillation from the same 
preparation. (B) PPADS did not have a significant treatment effect on mean bladder afferent nerve 
frequency (imp/sec) relative to control. (C) Representative traces of vehicle (gray) and recombinant TGF-
β1 (10 ng/ml, black) and PPADS (300 μM, black) co-instillation from the same preparation. (D) 
Concurrent instillation of TGF-β1 and PPADS attenuated distention-evoked bladder afferent nerve 
hyperexcitability mediated by TGF-β1. (E) TGF-β1 significantly increased distention-evoked ATP release 
at 25 mmHg when co-administered with PPADS. (F) Proposed mechanisms of purinergic signaling with 
TβR activation and PPADS. n=4-5; values are mean ± SEM. #p ≤ 0.05 by Student’s paired t test.  
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Figure 6: SB505124 decreased distention-evoked bladder afferent nerve hyperexcitability and ATP 
release with CYP-induced cystitis 
(A) Representative traces of CYP-induced cystitis (gray) and control (black) instillation. (B) CYP-induced 
cystitis significantly increased mean bladder afferent nerve frequency (imp/sec) by 188.9% relative to 
control with significant nerve discharge increase from 5-10, 10-15, 15-20 and 20-25 mmHg. (C) 
Representative traces of CYP-induced cystitis (gray) and SB505124 (5 μM, black) instillation from the 
same CYP preparation. (D) SB505124 significantly decreased mean bladder afferent nerve frequency 
(imp/sec) by 40.6% relative to CYP with significant nerve discharge decrease from 5-10, 10-15 and 15-20 
mmHg. (E) SB505124 significantly decreased distention-evoked ATP release with CYP-induced cystitis. 
(F) Proposed mechanisms of purinergic signaling with TβR inhibition and CYP-induced cystitis. n=4-19; 
values are mean ± SEM; *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001 by two-way repeated measures ANOVA 
followed by Sidak’s multiple comparisons test. #p ≤ 0.05 by Student’s paired t test.  
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
4.1. Summary 
BPS/IC is a chronic pain syndrome characterized by lower urinary tract 
symptoms and pain or discomfort thought to be bladder related. BPS/IC impacts the 
quality of life of the 3.3-7.9 million women (>18 years old) in the United States who 
exhibit symptoms and burdens the economy with significant financial ramifications 
(Berry et al., 2011). Currently, the etiology of altered visceral sensation that accompanies 
BPS/IC is not known. We propose that neurochemical alterations in the urinary bladder 
contribute to peripheral afferent activation and sensitization to underlie bladder 
dysfunction (Figure 1). The studies in this dissertation identified and described one 
potential inflammatory mediator, TGF-β, that may be used as a diagnostic marker and/or 
target in the lower urinary tract to improve function with urinary bladder inflammation. 
The following sections will discuss its clinical implications and the potential to expand 
this work. 
4.2. Summary and Future Directions: ATP Release 
The sensory processing of bladder filling is proposed to involve the release of 
ATP from the urothelium and the activation of P2X3 and P2X2/3 receptors on afferent 
nerve terminals (Kaan et al., 2010; Rong, Spyer, & Burnstock, 2002). Any perturbation 
that increases ATP release may therefore alter nerve excitability and underlie the 
development of micturition reflex dysfunction. We first demonstrated that aberrant TGF-
β signaling contributed, in part, to altered ATP release following CYP-induced cystitis 
(Figure 1). We next determined that TGF-β1 can directly stimulate the release of ATP 
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from the urothelium and that the effect was specific to receptor activation because the co-
administration with a TβR-1 inhibitor attenuated ATP release (Figure 1). We also 
determined that vesicular exocytosis mechanisms contributed more than pannexin-1 
channels to ATP release mediated by TGF-β1 (Figure 1). 
Our current studies were limited to measuring the luminal content of ATP due to 
methodological limitations. To confirm that TGF-β1 also stimulates basolateral ATP 
release that may then directly activate bladder afferent nerve terminals, we would use 
urothelial sheets in an Ussing chamber. The Ussing chamber would allow us to separate 
the mucosal and serosal compartments of the urothelium to measure ATP release into 
each chamber. Similar to other studies, we would expect that the luminal application of 
ATP would increase serosal ATP release (Sun & Chai, 2006). We would also expect the 
luminal application of TGF-β1 to increase serosal ATP release. While the addition of 
these experiments would strengthen our overall conclusions, the functional changes we 
observed in bladder-pelvic nerve preparations suggest we are altering the basolateral 
release of neuroactive transmitters. 
A mechanism that is not yet known in our model is the intracellular signaling 
cascade that TGF-β activates to stimulate ATP release. ATP release can be regulated, in 
part, by increases in intracellular calcium (McLatchie & Fry, 2015) and PKA second 
messenger cascades (Wang et al., 2005). Previous studies have reported that TGF-β can 
induce a sustained increase in intracellular calcium through type III IP3 receptors 
(McGowan et al., 2002). TGF-β has also been demonstrated to activate PKA, a response 
that was independent to an increase in cAMP (Zhang et al., 2004). We can examine these 
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mechanisms through various experiments that include chelating and reducing 
intracellular calcium with BAPTA-AM, inhibiting calcium release from IP3-dependent 
stores in the ER with 2-aminoethoxydiphenylborate (APB) (Ma, Venkatachalam, Parys, 
& Gill, 2002) and blocking PKA with cell permeable inhibitors H89 or PKI (5-24). These 
experiments would give us further insight into the intracellular mechanisms that underlie 
TGF-β mediated ATP release and may provide another target to improve voiding 
dysfunction. 
 
Figure 1: Schematic of TGF-β and purinergic signaling within the sensory components of the urinary 
bladder 
TβR activation evokes ATP release from urothelial cells through vesicular exocytosis mechanisms. These 
extracellular nucleotides may activate P2X/P2Y receptors on underlying cells, including afferent nerve 
terminals, to increase excitability. The resultant afferent nerve hyperexcitability may alter the sensory 
processing of bladder filling and contribute to increased voiding frequency. Abbreviations: ATP, adenosine 
triphosphate; BFA, brefeldin A; Ca++, calcium; Det, detrusor; G, g-protein coupled receptor; ICC, 
interstitial cells of Cajal; Na+, sodium; P2, purinergic receptor; Panx, pannexin; PPADS, 
pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid; TβR, transforming growth factor-beta receptor. 
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4.3. Summary and Future Directions: Afferent Limb of the Micturition Reflex 
Our studies demonstrated a role for TGF-β signaling in the afferent limb of the 
micturition reflex because intravesical TGF-β1 instillation increased bladder afferent 
nerve frequency and intravesical TβR-1 inhibition with SB505124 decreased bladder 
afferent nerve excitability and decreased voiding frequency following CYP-induced 
cystitis. TGF-β may alter nerve excitability indirectly by enhancing the release of 
neuroactive molecules from the urothelium or directly by activating receptors on nerve 
terminals. Our studies suggest that the intravesical treatment instillation was likely having 
an indirect effect on nerves through the urothelium and purinergic signaling (Figure 1). In 
addition to TGF-β1 stimulating ATP release, TGF-β1 affected nerve excitability in 
control tissues with an intact barrier suggesting a role for urothelial sensory processing 
(Figure 1). These experiments, however, cannot discount the possible direct effect on 
nerve terminals that TGF-β1 may be having in CYP-induced cystitis. 
Future studies can use whole-cell patch-clamp recording techniques to examine 
the direct role of TGF-β1 on primary afferent cell bodies (dorsal root ganglia) innervating 
the urinary bladder. Neurons projecting from the urinary bladder would first be labeled 
with fast blue and then selected for intracellular recordings. We would expect TGF-β1 to 
contribute to peripheral sensitization by increasing spontaneous and evoked action 
potentials as previously described (Zhu et al., 2012). Several mechanisms have been 
proposed to underlie this TGF-β mediated excitability. The phosphorylation of TRPV1 
by TGF-β mediated upregulation of Cdk5 has previously been shown to induce 
hyperexcitability in sensory neurons (Utreras et al., 2012). Similarly, TGF-β has been 
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previously shown to modulate KCNA4 transcript expression in sensory neurons resulting 
in a decrease of IA currents and hyperexcitability (Zhu et al., 2012). Future experiments 
may look at these mechanisms within urinary bladder sensory neurons to determine if 
they have a role in CYP-induced cystitis. 
4.4. Future Directions: Detrusor Smooth Muscle 
TGF-β can affect smooth muscle cell contractility by altering cytoskeletal (Hu et 
al., 2006) and contractile protein expression (Grainger, Metcalfe, Grace, & Mosedale, 
1998). TGF-β1 has also been demonstrated to increase contractility of primary human 
bladder smooth muscle cells through the effector JunB (Ramachandran et al., 2013). 
Since TGF-β1 is increased in the detrusor smooth muscle with intermediate (48 h) CYP-
induced cystitis, we would expect to see similar functional changes in contractility. We 
would determine the contribution of aberrant TGF-β signaling to detrusor contractility 
with CYP-induced cystitis using detrusor smooth muscle strips suspended from force 
transducers. We would first confirm previous studies that showed an increase in 
spontaneous contractions with CYP-induced cystitis (Okinami et al., 2014). We would 
next superfuse the TβR-1 inhibitor, SB505124, through the bath solution and expect to 
observe an inhibition of TGF-β1-induced contractility. 
The isolation of smooth muscle strips may not completely reflect intravesical 
pressure changes in open outlet cystometry because of not having an intact micturition 
reflex. As a result, these studies must be interpreted cautiously and in the context of the in 
vivo cystometrogram measurements. Our cystometry data demonstrated no changes in 
intravesical pressure (filling, threshold and peak) following CYP-induced and the 
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intravesical instillation of SB505124. This suggests that the detrusor smooth muscle was 
not involved in the decreased voiding frequency and increased bladder capacity, void 
volume and longer intercontraction intervals we observed. An alternative explanation is 
that while TβR-1 inhibition may alter contractility, SB505124 is simply not reaching the 
detrusor smooth muscle with intravesical instillation. Future studies can circumvent this 
problem and determine its involvement by administering SB505124 intravenously so that 
it can more readily access the smooth muscle. 
4.5. Future Directions: Somatic Hypersensitivity 
BPS/IC is characterized by pain perceived to emanate from the urinary bladder. 
In modeling this syndrome, CYP-induced cystitis has been demonstrated to increase 
hindpaw and pelvic somatic sensitivity (Arms, Girard, Malley, & Vizzard, 2013). Given 
the role of TGF-β1 in central and peripheral sensitization (Lantero, Tramullas, Diaz, & 
Hurle, 2012), we would expect to see a contribution of TGF-β1 to somatic 
hypersensitivity. Von Frey monofilaments can be used to determine referred pelvic and 
hindpaw sensitivity in CYP-treated animals with TβR-1 inhibition. The animals would be 
placed in a plexiglass chamber with a wire mesh floor and then tested for tactile allodynia 
and secondary hyperalgesia using these calibrated filaments to the abdomen and hindpaw. 
We would expect the intravesical instillation of SB505124 to decrease tactile allodynia 
and secondary hyperalgesia as evidenced by decreased withdrawal frequencies relative to 
baseline measurements in CYP-treated animals. The addition of these experiments would 
determine the role(s) of TGF-β1 in the development of somatic pain symptoms with 
cystitis. 
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4.6. Clinical Implications 
The neural circuitry underlying the micturition reflex is complex and is often 
compromised with neural injury, disease or inflammatory conditions. Our studies utilized 
the preclinical CYP-induced cystitis model to characterize the neurochemical plasticity in 
the sensory components of the urinary bladder. We demonstrated elevated levels of TGF-
β ligands and their cognate receptors following cystitis and determined their functional 
expression in the afferent limb of the micturition reflex. Given the diversity of bladder 
syndromes, it remains to be determined if certain inflammatory mediators and 
downstream signaling pathways are unique to specific conditions. Nevertheless, the 
inhibition of cytokine/receptor signaling may represent a therapeutic avenue for 
inflammation-associated bladder dysfunction. 
The presence of inflammatory molecules, like TGF-β, in the urine or urothelium 
may be a useful biomarker for monitoring inflammation or tracking responses to 
treatment in bladder syndromes. At this moment, the diagnostic criteria of BPS/IC are 
dependent on cystoscopy and symptom-based lower urinary tract dysfunction (Kuo, 
2014). Potential markers, such as elevated urinary proteins (Erickson et al., 2002) and 
serum cytokines (Jiang, Peng, Liu, & Kuo, 2013), have been suggested to permit an 
earlier treatment intervention to control or slow disease progression. Currently, however, 
these markers are likely not specific enough to differentially diagnose bladder syndromes 
(BPS/IC, OAB, etc.) (Kuo, 2014). While TGF-β may not be a diagnostic marker for 
BPS/IC, it does appear to offer an alternative method to track the progression of 
inflammation and tissue repair due to its temporal regulation in CYP-induced cystitis. 
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Future longitudinal studies must determine if inflammatory mediators, like TGF-β, 
follow this time course in clinical populations. The continued characterization of 
neurochemical alterations in bladder syndromes may improve patient outcome by 
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Abstract 
Bladder pain syndrome (BPS)/interstitial cystitis (IC) is a chronic bladder disorder 
characterized by pressure, discomfort, and pain perceived to be related to the urinary 
bladder, with at least one urinary symptom. We hypothesized that cyclophosphamide 
(CYP)-induced cystitis results in oxidative stress and contributes to urinary bladder 
dysfunction.  We determined: (1) the expression of oxidative stress markers (3-
nitrotyrosine (3-NT), reactive oxygen species (ROS)/reactive nitrogen species (RNS), 
inflammatory modulators, neuropeptides (calcitonin gene-related peptide (CGRP); 
substance P (Sub P), and adenosine triphosphate (ATP) that contribute to the 
inflammatory process in the urinary tract and (2) the functional role of oxidative stress in 
urinary bladder dysfunction with an antioxidant, Tempol (1 mM in drinking water) 
combined with conscious cystometry. In CYP-treated (4 hr of 48 hr; 150 mg/kg, i.p.) rats, 
ROS/RNS and 3-NT significantly (p ≤ 0.01) increased in urinary bladder. CYP-treatment 
increased ATP, Sub P and CGRP expression in the urinary bladder and cystometric fluid. 
In CYP-treated rats, Tempol significantly (p ≤ 0.01) increased bladder capacity, and 
reduced voiding frequency compared to CYP-treated rats without Tempol.  Tempol 
significantly (p ≤ 0.01) reduced ATP expression, 3-NT and ROS/RNS expression in the 
urinary tract of CYP-treated rats.  These studies demonstrate that reducing oxidative 
stress in CYP-induced cystitis improves urinary bladder function and reduces markers of 
oxidative stress and inflammation. 
Keywords: reactive oxygen species, reactive nitrogen species, 3-nitrotyrosine, ATP, 
neuropeptides, cystometry 
182 
   
Introduction 
Bladder pain syndrome (BPS)/interstitial cystitis (IC) is a chronic syndrome 
characterized by pressure, discomfort, and pain thought to arise from the urinary bladder, 
with at least one urinary symptom [1, 2]. While the underlying etiology of BPS/IC is not 
known, the majority of biopsies from BPS/IC patients reveal inflammation [3]. Mediators 
of inflammation, including cytokines, chemokines, growth factors and neuropeptides, 
have been shown to contribute to urinary bladder dysfunction and somatic sensitivity in 
animal models of cystitis and in the clinical syndrome of BPS/IC [3, 4]. In addition, 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) generated by 
inflammation result in oxidative stress and may contribute to urinary bladder dysfunction 
[5, 6]. The role(s) oxidants may have in inducing inflammation has been extensively 
studied in diverse experimental models [7]. Although it is widely accepted that ROS/RNS 
are fundamentally involved, antioxidant therapy as a valid means of arresting 
inflammation remains largely unresolved especially in the context of urinary bladder 
inflammation. 
 Accompanying oxidative stress and inflammatory mediator upregulation, the 
urothelium may also respond to cystitis by increasing the secretion of neuroactive factors, 
such as ATP, that signal to the underlying nerve plexus [8]. Altered release of these 
neuromodulatory compounds has been suggested to contribute to increased sensory 
transduction and result in urinary bladder dysfunction [4, 8]. In BPS/IC, for example, 
distention-evoked release of ATP was increased in tissue biopsies that may have resulted 
in the elevated urinary ATP observed in patients with BPS/IC [9]. Similarly, numerous 
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animal models of cystitis have demonstrated increased distention-evoked release of ATP 
from the urothelium [10, 11]. Further, purinergic receptor activation has been associated 
with increased cellular production and release of multiple inflammatory mediators, 
including superoxide anion, nitric oxide and other ROS [12].  Purinergic receptor 
activation induces ROS generation in numerous cell types resulting in a variety of 
downstream effects including, transcription factor activation [13], pro-inflammatory 
cytokine release [14, 15] and cell death [16]. 
 Using a rat model of urinary bladder inflammation induced by 
cyclophosphamide (CYP) [3, 4, 17, 18], we determined: (1) the expression of oxidative 
stress markers (3-nitrotyrosine (3-NT), ROS/RNS) and other modulators of 
inflammation, the neuropeptides calcitonin gene-related peptide (CGRP) and substance P 
(Sub P) in the urinary tract; (2) the contribution of ROS/RNS to ATP expression in the 
urinary bladder and urine with an antioxidant and superoxide dismutase mimetic, Tempol 
(1 mM in drinking water); and (3) the role of ROS/RNS in urinary bladder function with 
Tempol combined with open outlet, conscious and continuous intravesical infusion [19] .  
Although the etiology of BPS/IC is unknown, previous studies [3, 4, 17, 18] have 
demonstrated that the rat CYP model of urinary bladder inflammation is a reliable and 
reproducible model with face validity (e.g., increased voiding frequency and referred 
somatic sensitivity) to BPS/IC.  Previous studies have demonstrated roles for 
neuropeptides, including CGRP and Sub P, in CYP-induced bladder dysfunction [39, 57] 
and the current studies have continued to focus on these two neuropeptides, abundantly 
expressed in bladder sensory pathways. 
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Materials and Methods 
Animals 
 Adult female, Wistar rats (200-225 g; Charles River, St. Constant, Canada) were 
used for this study.  Rats were housed two per cage and maintained in standard laboratory 
conditions with free access to food and water.  The University of Vermont Institutional 
Animal Care and Use Committee approved all animal use procedures (protocol 08-085).  
Animal experimentation was carried out in accordance with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals.  All efforts were made to 
minimize the potential for animal pain, stress or distress. 
Induction of cyclophosphamide (CYP)-induced cystitis   
 Rats were anesthetized under isoflurane (2%) and acute cystitis was induced 
with a single injection of CYP (150 mg/kg, i.p.) and used in studies at various time points 
(4 hours (hr) or 48 hr) after treatment [20-22]. Control rats received volume-matched 
injections of saline (0.9%; i.p.) or no treatment and no difference among the control 
groups was observed. All injections were performed under isoflurane (2%) anesthesia. 
The CYP model of bladder inflammation produces an increase in voiding frequency with 
small micturition volumes and is associated with inflammatory cell infiltrates in the 
urinary bladder including mast cells, macrophages and neutrophils [23, 24].  Rats were 
euthanized using isoflurane (5%) and a thoracotomy.  
 For cystometry in conscious rats, an unrestrained animal was placed in a 
Plexiglas cage with a wire bottom. Before the start of the recording, the bladder was 
emptied and the catheter was connected via a T-tube to a pressure transducer (Grass 
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Model PT300, West Warwick, RI) and microinjection pump (Harvard Apparatus 22, 
South Natick, MA). A Small Animal Cystometry Lab Station (MED Associates, St. 
Albans, VT) was used for urodynamic measurements [19, 28]. Saline solution was 
infused at room temperature into the bladder at a rate of 10 ml/h to elicit repetitive 
bladder contractions. At least six reproducible micturition cycles were recorded after the 
initial stabilization period of 25–30 min [19, 28].  The following cystometric parameters 
were recorded in each animal: baseline pressure (BP; pressure at the beginning of the 
bladder filling), threshold pressure (TP; bladder pressure immediately prior to 
micturition), peak micturition pressure (MP), intercontraction interval (ICI; time between 
micturition events), bladder capacity (BC), void volume (VV), presence and amplitude of 
non-voiding bladder contractions (NVCs) [19, 28].  NVCs were defined as rhythmic 
intravesical pressure increases 7 cm H20 above baseline, during the filling phase, without 
the release of fluid from the urethra.  Bladder capacity (BC) was measured as the volume 
of saline infused into the bladder at the time when micturition commenced [35].  In these 
rats, residual volume was less than 10 μl; therefore, VV and BC were similar.  After the 
initial stabilization period, cystometric fluid expelled during micturition events was 
collected and frozen on dry ice and stored at -80 ˚C for future use in the assays described 
above.  At the conclusion of the experiment, the rat was euthanized (5% isoflurane plus 
thoracotomy), the urinary bladder was harvested and used in the assays described above. 
Split bladder preparation and assessment of potential contamination of bladder layers 
 The urothelium + suburothelium was dissected from the detrusor smooth muscle 
using fine forceps under a dissecting microscope as previously described [20, 21].   To 
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confirm the specificity of our split bladder preparations, urothelium + suburothelium and 
detrusor samples were examined for the presence of α-smooth muscle actin (1:1000; 
Abcam, Cambridge, MA) and uroplakin II (1:25; American Research Products, Belmont, 
MA) by western blotting or reverse transcription PCR [20, 25].  In urothelium + 
suburothelium layers, only uroplakin II was present (data not shown).  Conversely, in 
detrusor samples, only α-smooth muscle actin was present (data not shown).  All 
subsequent measurements of urinary bladder and cystometric fluid samples and conscious 
cystometry in rat groups were performed in a blind manner. 
Substance P (Sub P), calcitonin gene-related peptide (CGRP), 3-nitrotyrosine (3-NT) by 
enzyme-linked immunosorbent assays (ELISAs)  
 Tissue processing and ELISAs were performed as described previously [18, 26]. 
Briefly, rats from control (n = 6 each) and all experimental groups (n = 6 each) were 
deeply anesthetized (4% isoflurane), and a thoracotomy was performed. Individual rat 
bladders were dissected, weighed, and placed in Tissue Protein Extraction Reagent (1 g 
tissue/20 ml; Pierce Biotechnology, Woburn, MA) with Complete protease inhibitor 
cocktail tablets (Roche Applied Science, Mannheim, Germany), and stored at −80 °C. On 
the day of assay, individual bladders were disrupted with a Polytron homogenizer until 
homogeneous and centrifuged (10,000 rpm for 10 min) [18, 26], and the supernatant was 
used for total protein estimation and CGRP (Phoenix Pharmaceuticals, Inc. Burlingame, 
CA), Sub P (Phoenix Pharmaceuticals) and 3-NT (Millipore Corporation, Bellerica, MA) 
quantification. Total protein was determined by the Coomassie Plus Protein Assay 
Reagent Kit (Pierce) [18, 26] and CGRP, Sub P and 3-NT were quantified using standard 
187 
   
96-well ELISA plates (Phoenix Pharmaceuticals; Millipore Corporation) according to the 
manufacturer's recommendations.  For determination of Sub P and CGRP content in 
voided cystometric fluid, void volumes were collected following each micturition event 
in control and CYP-treated groups with and without Tempol (only vehicle) 
administration during conscious cystometry (see below). For Sub P, CGRP and 3-NT 
measurements in voided cystometric fluid, 6–8 individual voids/animal were collected 
and immediately frozen on dry ice.  Data from multiple voids were averaged, and the 
mean value was used for each animal.  
ELISAs for CRGP, Sub P, 3-NT expression in urinary bladder and voided cystometric 
fluid 
 The microtiter plates (Phoenix Pharmaceuticals; Millipore Corporation) were 
coated with mouse anti-rat CGRP, anti-rat Sub P or anti-rabbit-NT antibody. Sample and 
standard solutions were run in duplicate. Horseradish peroxidase (HRP)-streptavidin or 
HRP-conjugated goat anti-rabbit IgG and LumiGLO was used to detect the antibody 
complex. Tetramethylbenzidine or LumiGLO was the substrate, and the enzyme activity 
or luminescence was measured. The CRGP standard provided with this protocol 
generated a standard curve from 0 to 100 ng/ml (R2 = 0.998, P ≤ 0.0001) for bladder 
samples [26]. The Sub P standard provided with this protocol generated a standard curve 
from 0 to 25 ng/ml (R2 = 0.998, P ≤ 0.0001) for bladder samples [26].  The nitrated-BSA 
standard provided with this protocol generated a standard curve from 1.5 to 100 µg/ml 
(R2 = 0.997, P ≤ 0.0001) for bladder samples.  The absorbance values of standards and 
samples were corrected by subtraction of the background value (absorbance due to 
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nonspecific binding) [18, 26]. No samples were diluted and all samples had absorbance 
values that fell onto the linear portion of the standard curve. Curve fitting of standards 
and evaluation of protein content of samples were performed using a least-squares fit.  
Measurement of cellular oxidative stress  
 The levels of cellular oxidative stress were determined by a spectrofluorimetric 
method, using the dichlorofluorescein DiOxyQ (DCFH-DiOxyQ) assay (OxiSelect In 
Vitro ROS/RNS Assay Kit (Green Fluorescence; Cell Biolabs, Inc., San Diego, CA, 
USA). The urinary bladder was removed from control (n = 6 each) and all experimental 
groups (n = 6 each) and rapidly homogenized in 50 mM Tris–Cl, pH 7.4. The 
homogenate was centrifuged at 2400g for 15 min at 4 °C and a low-speed supernatant 
fraction was used for assays.  To determine levels of cellular oxidative stress, the 
supernatant from the urinary bladder homogenate was diluted (1:10) in 50 mM Tris–HCl 
(pH 7.4) and incubated with 10 μl of 2′,7′-DCHF-DA (1 mM), at 37 °C for 30 min.  The 
DCHF-DA is enzymatically hydrolyzed by intracellular esterases to form nonfluorescent 
DCFH, which is then rapidly oxidized to form highly fluorescent 2′,7′-
dichlorofluorescein (DCF) in the presence of cellular oxidative stress species. DCF 
fluorescence intensity is proportional to the amount of cellular oxidative stress species 
that is formed. The DCF fluorescence intensity emission was recorded at 520 nm (with 
480 nm excitation) 30 min after the addition of DCHF-DA to the sample. The cellular 
oxidative species levels were expressed as fluorescence arbitrary units (FAU). 
Collection and measurement of urinary ATP 
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Sample collections.  For determination of ATP in urinary bladder, urinary bladder harvest 
and subsequent processing was performed as described above for ELISAs.  For 
determination of ATP content in voided cystometric fluid, void volumes were collected 
following each micturition event in animal groups (control, CYP-treated groups, with and 
without Tempol) during conscious cystometry. For ATP measurements in voided 
cystometric fluid, 6–8 individual voids/animal were collected and immediately frozen on 
dry ice and stored at -80 ˚C until use.  Undiluted cystometric fluid samples were 
defrosted till 25°C, centrifuged at 3000g at room temperature for 20 seconds to remove 
cellular debris and the supernatant was separated. Data from multiple voids were 
averaged, and the mean value was used for each animal.   
ATP determination.  A mixture of luciferin-luciferase was added according to the 
manufacturer instructions using the ATP Bioluminescence Assay Kit HS II (Adenosine 
Triphosphate (ATP) Bioluminescent Assay Kit, Sigma-Aldrich, St. Louis, MO, USA) as 
previously described [27]. ATP detection was evaluated using a multi-mode microplate 
reader (Synergy HT, BioTek Instruments Inc., Vermont, USA) controlled with Gen5™ 
Data Analysis Software (BioTek). Sample bioluminescence was compared to that of 
standard amounts of ATP used in the same concentration range; standard ATP samples 
were prepared daily. All samples were run in duplicate.  Cystometric void data were 
obtained from at least three voids/animal from control (n = 6 each) and all experimental 
groups (n = 6 each) and urinary bladder data were obtained from control (n = 6 each) and 
all experimental groups (n = 6 each).  Vehicle for Tempol did not affect the ATP 
determinations. The ATP in cystometric fluid or ATP content in urinary bladder was 
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calculated relative to the standard curve, and expressed as nmol per total protein or nmol 
per ml of urine. 
Conscious Cystometry and effects of Tempol, a superoxide dismutase (SOD) mimetic 
Rats were anesthetized with isoflurane (3-4%), a lower midline abdominal 
incision was made, and polyethylene tubing (PE-50, Clay Adams, Parsippany, New 
Jersey) was inserted into the bladder dome and secured with a nylon purse-string sutures 
(6-zero) [19, 28]. The end of the PE tubing was heat flared, but the catheter did not 
extend into the bladder body or neck and it was not associated with inflammation or 
altered cystometric function [19, 28]. The distal end of the tubing was sealed, tunneled 
subcutaneously and externalized at the back of the neck out of reach of the animal [19, 
28]. Abdominal and neck incisions were closed with nylon sutures (4-zero). 
Postoperative analgesics were given and animals were maintained for 72 to 96 hours after 
survival surgery to ensure recovery. 
 Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl), a superoxide 
dismutase (SOD) mimetic,  is a stable nitroxyl antioxidant. Previous studies have 
suggested that Tempol is protective in disorders involving ROS [29-32].  The effects of 
Tempol on urinary bladder function in CYP-treated (4 hr and 48 hr; n = 6 each) rats and 
control rats (n = 6 each) were assessed using conscious, open outlet, cystometry with 
continuous instillation of intravesical saline [19, 28].  Tempol was prepared daily with 
distilled water purified with a Millipore Milli-Q system and administered in the drinking 
water (1 mM) that was provided to rats ad libitum; untreated rats received water ad 
libitum.  Covered bottles were used to minimize degradation by light.  The addition of 
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Tempol to the drinking water did not affect water consumption (data not shown).  For 
CYP-treated rat groups (4 hr, 48 hr), Tempol was provided for approximately two weeks 
(13-15 days) while the intravesical tube was implanted on day 10, CYP or vehicle was 
injected on day 13 and rats were used in experiments on day 13-15.  Due to the daily 
administration and route of delivery (oral) of the Tempol, these experiments were 
performed in different groups of control and CYP-treated rats treated with vehicle or 
Tempol. The concentration (1 mM) of Tempol and duration of treatment used in these 
studies was based upon previous studies [33, 34].  
Exclusion Criteria 
 Rats were removed from the study when adverse events occurred that included 
20% reduction in body weight post-surgery, a significant postoperative event, lethargy, 
pain, or distress not relieved by our IACUC-approved regimen of postoperative 
analgesics or hematuria in control rodents [19, 28]. In the present study, no rats were 
excluded from the study. In addition, behavioral movements such as grooming, standing, 
walking, and defecation rendered bladder pressure recordings during these events 
unusable.  
Statistical Analyses 
 All values represent mean ± SEM.  Cystometry data were compared using 
repeated measures ANOVA, where each animal served as its own control. Animals, 
processed and analyzed on the same day, were tested as a block in the ANOVA. When F-
ratios exceeded the critical value (p ≤ 0.05), the Newman-Keuls or Dunnett's post hoc 
tests were used to compare group means. Data obtained from the ATP assays violated the 
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assumptions of the ANOVA. Thus, these data were analyzed using a non-parametric 
analysis, the Mann-Whitney Rank Sum test. When F ratios exceeded the critical value (p 
≤ 0.05), the Newman-Keul's post-hoc test was used to compare the experimental means.  
P ≤ 0.05 (two-tailed) values were considered statistically significant. 
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Results 
ROS/RNS Expression in Urinary Bladder with CYP-induced Cystitis and the Effects of 
Tempol 
We determined the levels of reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) in the urinary bladder following CYP treatment (4 hr, 48 hr) and 
in the presence of the antioxidant, Tempol.  4 hr and 48 hr CYP-induced cystitis 
significantly (p ≤ 0.01) increased the total free radical presence in the detrusor and 
urothelium that was significantly reduced (p ≤ 0.01) by Tempol (1 mM) delivered in the 
drinking water (Figure 1A).  With both 4 hr and 48 hr CYP-induced cystitis, the increase 
in total free radical presence was significantly (p ≤ 0.01) greater in the detrusor compared 
to the urothelium (Figure 1A).  Basal expression of total free radical presence in the 
detrusor was significantly (p ≤ 0.01) greater in the detrusor compared to the urothelium 
(Figure 1A). 
3-Nitrotyrosine (3-NT) Expression in Urinary Bladder with CYP-induced Cystitis and the 
Effects of Tempol 
3-NT, a product of tyrosine nitration mediated by RNS such as peroxynitrite 
anion and nitrogen dioxide, is considered a marker of NO-dependent, RNS-induced 
nitrative stress [36].  4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01) 
increased 3-NT expression in the urinary bladder that was significantly reduced (p ≤ 
0.01) by Tempol (1 mM) delivered in the drinking water (Figure 1B).  3-NT expression 
in the urinary bladder was significantly (p ≤ 0.01) greater following 4 hr CYP-induced 
cystitis compared to 48 hr CYP-induced cystitis (Figure 1B).  
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Substance P (Sub P) and Calcitonin Gene-Related Peptide (CGRP) Expression in 
Urinary Bladder and Cystometric Fluid with CYP-induced Cystitis and the Effects of 
Tempol 
The neuropeptides, Sub P and CGRP, are known modulators of inflammation 
and may contribute to the pathogenesis of many diseases including migraine, asthma, and 
urinary bladder inflammation [4, 37-39].  4 hr and 48 hr CYP-induced cystitis 
significantly (p ≤ 0.01) increased Sub P and CGRP expression in the urinary bladder 
(Figure 2A; Figure 3A) and cystometric fluid (Figure 2B; Figure 3B) that was 
significantly reduced (p ≤ 0.01) by Tempol (1 mM) delivered in the drinking water 
(Figure 2A, 2B; Figure 3A, 3B).  Sub P expression in the urinary bladder was similar 
following 4 hr and 48 hr CYP-induced cystitis in the urinary bladder and cystometric 
fluid (Figure 2A, 2B).  In contrast, 48 hr CYP-induced cystitis resulted in significantly (p 
≤ 0.01) greater CGRP expression in the urinary bladder and cystometric fluid compared 
to the 4 hr time point (Figure 3A, 3B). 
Adenosine Triphosphate (ATP) Expression in Urinary Bladder and Cystometric Fluid 
with CYP-induced Cystitis and the Effects of Tempol 
Numerous studies have described a role(s) for ATP in urinary bladder 
dysfunction, pain and altered ATP release mechanisms in animal models and clinical 
studies of BPS/IC [8].  4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01) 
increased ATP expression in the urinary bladder and cystometric fluid that was 
significantly reduced (p ≤ 0.01) by Tempol (1 mM) delivered in the drinking water 
(Figure 4A, 4B).  ATP expression in the urinary bladder was similar following 4 hr and 
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48 hr CYP-induced cystitis (Figure 4A).  In contrast, 4 hr CYP-induced cystitis resulted 
in significantly (p ≤ 0.01) greater ATP expression in the cystometric fluid compared to 
the 48 hr time point (Figure 4B). 
Effect of an Antioxidant, Tempol, on Bladder Function 
Conscious, open outlet cystometry with continuous intravesical infusion of 
saline was performed in separate groups (n = 6 each) of control and CYP-treated (48 h) 
rats with or without Tempol (vehicle only) in the drinking water to determine bladder 
function (Figure 5; Figure 6; Figure 7; Figure 8). 
Control (no CYP treatment). 
Tempol (1 mM) treatment had no effects on ICI, BC, or VV in control rats (no 
CYP treatment) compared with control rats (no CYP treatment) treated with vehicle 
(Figure 5). There were no changes in BP, TP, or peak MP with Tempol treatment 
compared to control rats (no CYP treatment) treated with vehicle (Figure 6).  Residual 
volume in control rats with or without Tempol (vehicle) treatment was minimal (≤ 10 μl). 
CYP treatment. 
As previously demonstrated [20-22], and confirmed here, CYP treatment (4 hr 
and 48 hr) increased void frequency and decreased BC, ICI, and VV compared with 
control rats (no CYP treatment) (Figure 5; Figure 6; Figure 7; Figure 8). Additionally, 48 
hr CYP-induced cystitis significantly (p ≤ 0.01) increased BP and TP (Figure 6). Tempol 
in the drinking water (1mM) of CYP-treated rats (4 hr and 48 hr) significantly (p ≤ 0.01) 
increased the ICI (i.e., decreased voiding frequency) (Figure 5A; 2.0-2.9-fold), increased 
BC (Figure 5C; 2.8-3.1-fold), and increased VV (Figure 5B; 2.9-5.4-fold) compared to 
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rats treated with CYP (4 hr and 48 hr) receiving vehicle (Figure 7; Figure 8). Tempol 
treatment of CYP-treated rats (4 hr and 48 hr) increased BC to 70% of control rats (no 
CYP treatment) (Figure 5C; Figure 7; Figure 8). Effects of Tempol on bladder function in 
CYP-treated rats persisted for at least 2 hr. Residual volume in CYP (4 hr and 48 hr)-
treated rats with or without Tempol treatment was minimal and similar to that observed in 
control (no CYP treatment) (≤ 10 μl).  CYP-treated rats (4 hr and 48 hr) treated with or 
without Tempol (vehicle) exhibited no differences in BP, TP or peak MP (Figure 6A-C).  
Tempol also significantly (p ≤ 0.01) reduced the number (2.4 ± 0.4/micturition cycle vs. 
0.6 ± 0.2/micturition cycle) and amplitude (11.2 ± 1.3 cm H20 vs. 7.5 ± 0.5 cm H20) of 
NVCs (increases in bladder pressure during the filling phase without the release of fluid) 
in 4 hr CYP-treated rats (Figure 7).  The effects of Tempol on NVCs in the 48 hr CYP-
treated group were not determined due to the dramatically increased voiding frequency 
that made the presence of NVCs difficult to determine. 
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Discussion 
The present studies demonstrate several novel findings with respect to the 
induction and reduction of oxidative stress with the antioxidant, Tempol, following 
cyclophosphamide (CYP)-induced cystitis.   CYP-induced cystitis (4 hr and 48 hr) 
increased ROS/RNS and 3-NT expression in the urinary bladder.  In addition, CYP-
induced cystitis increased expression of neuropeptides, CGRP and Sub P, in the urinary 
bladder as well as cystometric fluid collected during conscious cystometry.  CYP-induced 
cystitis also increased ATP in the urinary bladder and cystometric fluid.  Providing rats 
with the antioxidant, Tempol, in the drinking water prior to and during the induction of 
CYP-induced cystitis significantly reduced the expression of ROS/RNS, CGRP, Sub P 
and ATP in urinary bladder and cystometric fluid.  Further, Tempol decreased voiding 
frequency, increased the intercontraction interval and bladder capacity without effects on 
urinary bladder pressures (baseline, threshold, peak) in rats with CYP-induced cystitis.  
Tempol did not alter bladder function in control (no CYP treatment) rats.  These studies 
demonstrate that CYP-induced cystitis is associated with oxidative stress in the urinary 
tract and that use of the antioxidant, Tempol, reduces oxidative stress and improves 
urinary bladder function. 
 Molecular oxygen reduction results in the production of several reactive 
intermediates that must be actively scavenged [40]. Under conditions of inflammation, 
there may be insufficient scavenging of reactive intermediates that can lead to oxidative 
stress and damage to cellular structure and function. Recent studies suggest the 
generation of these reactive intermediates contribute to the pathogenesis of urinary 
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bladder dysfunction with CYP administration [41-43]. The contribution of oxidative 
stress in bladder inflammation following CYP is further supported by the attenuation of 
tissue damage following the administration of agents with antioxidant properties, like 
taurine [41], flavonoid [42], beta-carotene and others [43]. Our studies using the CYP 
model of urinary bladder inflammation at two time points (4 hr and 48 hr) confirm the 
expression of reactive intermediates including ROS/RNS and 3-NT in the urinary 
bladder.   Expression of ROS/RNS following CYP-induced cystitis was significantly 
greater in the detrusor smooth muscle compared to the urothelium but both tissues 
exhibited increased ROS/RNS compared to control (no CYP treatment) urinary bladder. 
3-NT expression has been previously demonstrated in lower urinary tract tissues 
following injury or inflammation.  Partial outlet obstruction in rabbit is associated with 
increased NT in mucosa [44] that is correlated with progressive decrease in contractility 
of detrusor smooth muscle [45].  Previous studies demonstrated iNOS and NT 
immunoreactivity in the urothelium and inflammatory infiltrates in the lamina propria of 
individuals with BPS/IC with a Hunner’s lesion [47]. Consistent with this clinical study, 
the present study demonstrates increased 3-NT in the urinary bladder following CYP-
induced cystitis (4 hr and 48 hr) in a rat model.  The amino acid tyrosine is particularly 
susceptible to nitration and the formation of 3-NT may represent a biomarker for the 
generation of reactive nitrogen intermediates in vivo [47].  In addition to being a 
biomarker, 3-NT could also have a detrimental impact on cell function and viability by 
inhibiting protein phosphorylation by tyrosine kinases and interfering with the signal 
transduction mechanism [48]. In addition, in vitro nitration of a specific tyrosine residue 
199 
   
inactivates manganese superoxide dismutase [49] that may lead to a greater concentration 
of ROS/RNS perpetuating tissue damage and altered function. 
  As a major sensory component of the urinary bladder, the urothelium is able to 
respond to various extracellular stimuli by releasing neuroactive factors like ATP, 
acetylcholine and nitric oxide [8]. The sustained release of these factors, such as what 
may occur with inflammation, may underlie the development of urinary bladder 
dysfunction and lower urinary tract symptoms.  The role of oxidative stress with ATP 
release in epithelial cells, however, is not well defined.  In endothelial cells, oxidative 
stress has been demonstrated to mediate the direct release of ATP and inhibit the 
catabolism of extracellular ATP [50, 51].  Further, purinergic receptor activation has been 
associated with increased cellular production and release of multiple inflammatory 
mediators, including superoxide anion, nitric oxide and other ROS.  Purinergic receptor 
activation induces ROS generation in numerous cell types resulting in a variety of 
downstream effects including, transcription factor activation [13], pro-inflammatory 
cytokine release [14, 15] and cell death [16].  Our studies determined the contribution of 
ROS/RNS to extracellular ATP expression with CYP-induced cystitis and Tempol.  CYP-
induced cystitis increased ATP expression in the urinary bladder and cystometric fluid 
that was significantly reduced by Tempol administration.  It is not known from the 
present studies whether antioxidant treatment directly inhibits the release of ATP through 
purinergic receptor blockade.  Additional studies in CYP-treated rats involving 
assessment of oxidative stress in the presence of purinergic receptor (P2) blockade as 
well as the effects of P2 activation on oxidative stress in controls should be considered. 
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 Tempol is a membrane-permeable, redox-cycling agent that scavenges 
superoxide anions and decreases the formation of hydroxyl radicals [32]. The protective 
effects of Tempol to tissues with inflammation and oxidative damage have been widely 
established. For example, Tempol has been shown to decrease NF-kappaB activation 
with acute inflammation [52], decrease neutrophil infiltration and PARP activation with 
periodontitis [53], and decrease cytokine release stimulated by an inflammatory soup 
[54].  In animal studies, purinergic neuromuscular transmission and propulsive motility 
were significantly restored in the inflamed colon treated with the free radical scavenger, 
Tempol [55].  Furthermore, intrathecal Tempol administration has been demonstrated to 
decrease thermal and mechanical hypersensitivity with neuropathic pain [56]. Due to the 
central and peripheral anti-inflammatory properties of Tempol, our studies determined 
the role of oxidative stress on bladder function with CYP-induced cystitis and Tempol 
administration.  Pretreatment with Tempol and continued treatment with Tempol during 
the progression of CYP-induced cystitis significantly improved urinary bladder function.  
In CYP-treated (4 hr and 48 hr) rats, Tempol in the drinking water increased the 
intercontraction interval and bladder capacity and reduced urinary frequency.  The 
presence and amplitude of NVCs during the filling phase of the urinary bladder were also 
reduced in 4 hr CYP-treated rats given Tempol.  Given the demonstration of Tempol 
decreased mechanical hypersensitivity from neuropathic pain [56], future studies should 
examine the effects of Tempol administration on somatic (i.e., pelvic, hindpaw) 
sensitivity in CYP-treated rats.   
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 Previous studies from our laboratory have demonstrated roles for neuropeptides, 
including pituitary adenylate cyclase-activating polypeptide (PACAP), CGRP and Sub P 
in CYP-induced bladder dysfunction [39, 57].  Increased expression of PACAP, CGRP 
and Sub P were demonstrated in the urinary bladder, lumbosacral spinal cord and dorsal 
root ganglia of CYP-treated rats and pharmacological blockade of the PACAP specific 
PAC1 receptor improved urinary bladder function in CYP-treated rats [39, 57].  The 
present studies confirm increased expression of Sub P and CGRP in the urinary bladder 
and cystometric fluid with CYP-induced cystitis (4 hr and 48 hr).  Tempol treatment 
significantly reduced Sub P and CGRP expression in the urinary bladder and cystometric 
fluid.  Previous studies demonstrated that Sub P via neurokinin (NK) receptor facilitates 
bladder afferent signaling and ROS formation in bladder in association with neurogenic 
inflammation [58].  Increased Sub P release increased ROS in the bladder via increased 
mast cell degranulation, intercellular adhesion molecule expression, and leukocyte 
adhesion.  Future studies can determine the involvement of Sub P/NK receptor signaling 
with these sources of ROS in the inflamed bladder following CYP-induced cystitis. The 
neuropeptides, PACAP27, PACAP38 and VIP, evoked ATP release from rat urothelial 
cell cultures and significantly blocked by the PAC1 receptor selective antagonist, M65 
[27]. The present studies suggest two possibilities by which CYP-induced cystitis 
increases ATP expression in the urinary bladder and cystometric fluid:  1) neuropeptide 
(Sub P and CGRP) evoked release of ATP and 2) ROS evoked ATP release.  Current 
research is consistent with the suggestion that neuropeptide as well as ROS signaling are 
regulators of bladder physiology at the level of the urinary bladder and possibly, the 
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urothelium [27].  The present studies demonstrate that use of the antioxidant, Tempol, not 
only reduces the presence of oxidative stress markers in the urinary tract but also reduces 
modulators/mediators of inflammation including neuropeptides (CGRP, Sub P) also 
known to contribute to micturition reflex plasticity and dysfunction with CYP-induced 
cystitis.  In the context of CYP-induced cystitis, Tempol treatment may be more 
beneficial given its broader impact on oxidative stress markers and other modulators of 
urinary bladder inflammation while also improving urinary bladder function. 
 The present studies demonstrate oxidative stress in the urinary tract following 
CYP-induced cystitis and improvement in urinary bladder function and markers of 
oxidative stress with antioxidant treatment; however, there are additional issues to be 
considered.  Future studies may include: 1) determining the effects of Tempol after the 
induction of CYP-induced cystitis, rather than as a pretreatment, on urinary bladder 
function; 2) determining if Tempol treatment can reduce somatic sensitivity in the CYP 
model of urinary bladder inflammation with referred, somatic hypersensitivity; 3) 
determining the effects of Tempol in a more chronic model of CYP-induced urinary 
bladder inflammation that we have used extensively [23, 24].  The present studies 
demonstrate that CYP-induced cystitis results in oxidative stress in the urinary tract and 
that the antioxidant, Tempol, ameliorates CYP-induced bladder dysfunction. These 
studies suggest that pharmacological interventions directed at oxidative stress 
mediators/markers may be a promising strategy to address inflammation of the urinary 
tract and target organ dysfunction. 
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Figure 1: CYP-induced cystitis increases reactive oxygen species (ROS)/reactive nitrogen species 
(RNS) and 3-nitrotyrosine (3-NT) in the urinary bladder and the antioxidant, Tempol, reduces 
expression 
A. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01) increased ROS/RNS expression in 
urothelium and detrusor that was significantly (p ≤ 0.01) reduced with Tempol.  Basal expression and CYP-
induced ROS/RNS expression and was significantly (p ≤ 0.01) greater in detrusor compared to urothelium.  
Tempol was without effect on ROS/RNS expression in urothelium and detrusor from control (no CYP) rats.  
B. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01) increased ROS/RNS expression in urinary 
bladder that was significantly (p ≤ 0.01) reduced with Tempol.  Tempol was without effect on 3-NT 





   
 
Figure 2: CYP-induced cystitis increases substance P (Sub P) in the urinary bladder and cystometric 
fluid and the antioxidant, Tempol, reduces expression 
A. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01) increased Sub P expression in urinary 
bladder that was significantly reduced with Tempol.  Tempol was without effect on Sub P expression in 
urinary bladder from control (no CYP) rats.  B. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01) 
increased Sub P expression in cystometric fluid that was significantly (p ≤ 0.01) reduced with Tempol.  
Tempol was without effect on Sub P expression in cystometric fluid from control (no CYP) rats. *, p ≤ 
0.01.  n=6 for control and treatment groups. 
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Figure 3: CYP-induced cystitis increases calcitonin gene-related peptide (CGRP) in the urinary 
bladder and cystometric fluid and the antioxidant, Tempol, reduces expression.  
A. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01) increased CGRP expression in urinary 
bladder that was significantly (p ≤ 0.01) reduced with Tempol.  Tempol was without effect on CGRP 
expression in urinary bladder from control (no CYP) rats.  B. 4 hr and 48 hr CYP-induced cystitis 
significantly (p ≤ 0.01) increased CGRP expression in cystometric fluid that was significantly (p ≤ 0.01) 
reduced with Tempol. *, p ≤ 0.01.  n=6 for control and treatment groups. 
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Figure 4: CYP-induced cystitis increases adenosine triphosphate (ATP) in the urinary bladder and 
cystometric fluid and the antioxidant, Tempol, reduces expression 
A. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01) increased ATP expression in urinary bladder 
that was significantly (p ≤ 0.01) reduced with Tempol.  Tempol was without effect on ATP expression in 
urinary bladder from control (no CYP) rats.  B. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01) 
increased ATP expression in cystometric fluid that was significantly (p ≤ 0.01) reduced with Tempol.  
Tempol was without effect on ATP expression in cystometric fluid from control (no CYP) rats.  *, p ≤ 0.01.  
n=6 for control and treatment groups. 
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Figure 5: Summary histograms of the effects of Tempol (1 mM) on intercontraction interval (ICI; s), 
bladder capacity (BC; µl) and void volume (VV; ml) in CYP-treated (4 hr; 48 hr) rats 
Tempol in the drinking water significantly (p ≤ 0.01) increased ICI (A), VV (B) and BC (C) in CYP-treated 
(4 hr and 48 hr) rats.  Tempol was without effect in control (no CYP treatment) rats. *, p ≤ 0.01. Sample 
sizes are n = 6 in control and treatment groups. 
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Figure 6: Tempol in the drinking water was without effect on baseline pressure (A; BP), threshold 
pressure (B; TP) or peak micturition pressure (C; MP; cm H20) in control or CYP-treated (4 hr; 48 
hr) rats 




   
 
Figure 7: Representative cystometrogram recordings using continuous intravesical infusion of saline 
in conscious rats with an open outlet from a CYP-treated (4 hr) rat with vehicle (A1-A3) and a CYP-
treated (4 hr) rat with Tempol (1 mM; B1-B3) 
A,B: Bladder function in a CYP-treated (4 hr) rat without Tempol (vehicle only; A1-A3) and in a CYP-
treated (4 hr) rat with Tempol (1mM in the drinking water; B1-B3) during continuous intravesical infusion 
of saline.  Bladder function recordings in A and B are from different rats.  Infused volume (IF, µl; A1, B1), 
bladder pressure (BP, cm H2O; A2, B2), and void volume (VV, ml; A3, B3) with vehicle (A1-A3) and with 
Tempol treatment (B1-B3) are shown.  Arrows (A2, B2) indicate examples non-voiding contractions that 
were significantly (p ≤ 0.01) reduced in number and amplitude in CYP-treated (4 hr) rats with Tempol. 
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Figure 8: Representative cystometrogram recordings using continuous intravesical infusion of saline 
in conscious rats with an open outlet from a CYP-treated (48 hr) rat with vehicle (A1-A3) and a 
CYP-treated (48 hr) rat with Tempol (1 mM; B1-B3) 
A,B: Bladder function in a CYP-treated (48 hr) rat without Tempol (vehicle only; A1-A3) and in a CYP-
treated (48 hr) rat with Tempol (1mM in the drinking water; B1-B3) during continuous intravesical infusion 
of saline.  Bladder function recordings in A and B are from different rats. Infused volume (IF, µl; A1, B1), 
bladder pressure (BP, cm H2O; A2, B2), and void volume (VV, ml; A3, B3) with vehicle (A1-A3) and with 
Tempol treatment (B1-B3) are shown. 
